

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

ANNE RYAN & CO.
60 Northumberland Road
Ballsbridge
Dublin 4
IRLANDE

Date of mailing (day/month/year) 09 April 2001 (09.04.01)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference POO-18-PCT	
International application No. PCT/IE00/00026	International filing date (day/month/year) 28 February 2000 (28.02.00)

1. The following indications appeared on record concerning:

☒ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address

State of Nationality

IE

State of Residence

IE

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

McMAHON, Ruth, Anne
16 St. Patrick's Cottages
Rathfarnham
Dublin 14
Ireland

State of Nationality

IE

State of Residence

IE

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

Additional applicant/inventor for the US only.

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Maria Victoria CORTIELLO

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

ANNE RYAN & CO.
60 Northumberland Road
Ballsbridge
Dublin 4
IRLANDE

Date of mailing (day/month/year) 09 April 2001 (09.04.01)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference POO-18-PCT	
International application No. PCT/IE00/00026	International filing date (day/month/year) 28 February 2000 (28.02.00)

1. The following indications appeared on record concerning:

☒ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address	State of Nationality IE	State of Residence IE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address MURPHY, Madeline, Anne 53 Meadow Grove Churchtown Dublin 16 Ireland	State of Nationality IE	State of Residence IE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

Additional applicant/inventor for the US only.

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Maria Victoria CORTIELLO Telephone No.: (41-22) 338.83.38
--	---

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 16 October 2000 (16.10.00)	
International application No. PCT/IE00/00026	Applicant's or agent's file reference POO-18-PCT
International filing date (day/month/year) 28 February 2000 (28.02.00)	Priority date (day/month/year) 26 February 1999 (26.02.99)
Applicant BRADY, Hugh, Redmond et al	

1. The designated Office is hereby notified of its election made:


☒ in the demand filed with the International Preliminary Examining Authority on:

08 September 2000 (08.09.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Zakaria EL KHODARY
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference POO-18-PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IE00/00026	International filing date (day/month/year) 28/02/2000	Priority date (day/month/year) 26/02/1999
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant HIBERGEN LIMITED et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 10 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 08/09/2000	Date of completion of this report 07.06.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Luzzatto, E Telephone No. +49 89 2399 8169



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IE00/00026

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1,2,4-8,11-15,17-39, as originally filed
43,44

3,9,10,16,40-42 with telefax of 14/02/2001

Claims, No.:

1-11 with telefax of 14/02/2001

Sequence listing part of the description, pages:

1-11, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IE00/00026

- ☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:
see separate sheet

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-11
	No:	Claims	none
Inventive step (IS)	Yes:	Claims	1-11
	No:	Claims	none
Industrial applicability (IA)	Yes:	Claims	1-11
	No:	Claims	none

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

PART V

1) Novelty (Art. 33(2) PCT)

- a) None of the available documents discloses either a method for the identification of glucose regulated genes comprising the use of suppression subtractive hybridisation or the sequences SEQ ID 1-3, 5 and 6. The subject-matter of claim 1, of claims 2-7 dependent thereon and of claim 11 is thus novel (Art. 33(2) PCT).
- b) In view of the novelty of the said sequences, also claims 8-10, insofar as related thereto, are novel (as to claims 7-10 see also Part VIII hereinbelow).

2) Inventive step (Art. 33(3) PCT)

- a) D1 (BBRC, 179-84, 1997, Holmes et al.) teaches a method for the identification of glucose regulated genes in mesangial cells by mRNA differential display. The method comprises the culturing of the cells in the presence of a high glucose concentration (4 or 30 mM) and the detection of differentially expressed genes by the differential display method (see abstract, materials and methods). Various genes are detected, a few of them previously unknown (see fig. 3 and discussion). Starting from D1, the technical problem to be solved may be defined as that of providing an alternative method for the detection of glucose regulated genes. This problem is solved by the method of claim 1, which comprises the use of suppression subtractive hybridisation (SSH) instead of mRNA differential display (mRNA-DD) as in D1.

By the presently claimed method, the inventors were able to identify previously unknown genes which are glucose regulated.

Although SSH is a known technique (see p. 4, l. 1-14 of the application) there are no indications in any of the available documents that its application to the detection of glucose regulated genes would have lead to the identification of previously unknown genes. In view of this unexpected effect, the subject-matter of claim 1 is deemed to involve an inventive step.

The same applies to claims 2-7 dependent thereon and to claim 11.

- b) Claims 8-10, insofar as related to SEQ ID 1-6, also involve an inventive step since

the said sequences are either novel and inventive (SEQ ID 1-3,5-6) or have never been previously suggested to be linked to diabetic nephropathy (SEQ ID 4).

PART VII

- 1) Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this documents identified therein.

PART VIII

- 1) Claim 7 is unclear (Art. 6 PCT), because the genes detected by the method of claims 1-6 are not a technical feature of the method but merely represent the result of its application.
- 2) Claims 8-10 are not supported by the description (Art. 6 PCT) and their subject-matter contravenes Art. 5 PCT insofar as related to completely uncharacterised genes. SEQ ID 1-6 have been identified by the method of the invention, which is based on an accepted diabetic nephropathy model, and therefore their use as indicated in claims 8-10 can find support.

However, this does not apply to genes solely characterised in that they can be identified by the method of claims 1-7 and for which no further technical features are given in the said claims. The skilled person would not know which genes are covered by the claims and which are not.

Claims 8-10, therefore, should have been limited to clearly characterised genes, i.e. those comprising SEQ ID 1-6.

gene susceptible to such differential expression and identifying the gene so induced by suppression subtractive hybridisation.

5 Preferably, the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.

10 Further, preferably, the concentration of glucose is greater than 5 mM.

A concentration of 5 mM falls within the normal range of plasma glucose levels in a healthy human subject (4.2 – 6.4 mmol/l).

15 The concentration of glucose used is suitably in the range 5-30 mM. The concentration of 30 mM was chosen as the classic "*in vitro*" model of diabetic nephropathy which induces changes in mesangial function that mimic human disease. This level is also encountered in many diabetics *in vivo*.

20 In one embodiment, the mesangial cells are subjected to mechanical strain.

In a further embodiment, transforming growth factor β 1 (TGF- β 1) is added to the culture medium.

25

AAAATTATTTTTTATCTGCTGGCCTT (SEQ ID NO: 2)

.....ATGACACAAATATTAG
GATTTTATTTTTACTATTATCCACCAGCAACAAGATATCAAAC
ACTGGTTCTGTGATTATTTAATGGTGAAAAAGTTGAATAAATC
5 AATTTAGTATACCCATATGTTGGAATATTGAGTCCATTTTTCTT
TTAAAAATCACACTTTGGAATAATTGATGATACTGGCAAATGC
TCAAGCTGAGTGGAAAAATATATAAACATTGTATAGGCGAAT
AATTCCAATCTTGTGCATTCCCTGTGTAAACCTACATACACAA
AAAGAAAAAAGACTGAAAGGAACCATCCACAATGCTTTGATC
10 GGGAAAGACGGAGAAACAAAGTGTTAATTTTCTTAAGTATAG
TTTTNGGTGTATTCCAGATTTTCTACAAGTTAATA (IHG-1) (SEQ
ID NO: 3);

2)GTACTTTGGATTTGGTTAACCTGTTTTCTTCAAGCCTGAGGT
15 TTTATATACAAACTCCCTGAATACTCTTTTTGCCTTGTATCTTC
TCAGCCTCCTAGCCAAGTCCTATGTAATATGGAAAACAAACA
CTGCAGACTTGAGATTCAGTTGCCGATCAAGGCTCTGGCATTTC
AGAGAACCCTTGCAACTCGAGAAGCTGTTTTTATTTTCGTTTTT
GTTTTGATCCAGTGCTCTCCCATCTAACAACCTAAACAGGAGCC
20 ATTTCAAGGCGGGAGATATTTTAAACACCCAAAATGGTTGGG
TCTGATTTTCAAACCTTTTAAACTTCACTACTGATGATTCTGCA
CGCTAAGGCGAATTTGGTCCAAACACATAAGTGTGTGTGTTTT
GTATACACTGTATGACCCACCCCAAATCTTTGTATTGTCCAC
ATTCTCC IHG-2 (SEQ ID NO: 4);

25

3)AGAAGCAATTTAGGAANCCNACAGNAAANAAATGCTGTTTT
ATAGGAGAGAAAACACGGCACACCAAGGTTAAGTAGTTTGTA

GACGATGTTGAATAGGTTTCAGGTACAGGTCAATGCAGTGATG
AGGAAAGCACCTANGTATACTTGACAGATAGTCCCCTTTGCTT
AACACCCAACTCCTCCACCCTGTGCAGTTTNNCTTGTGCCAGT
GATCACAGGATTCGCTGAGTGAATTACCATAATTGGATTTAAT
5 TCACGAAGGGGATGTTTTTC (IHG-3) (SEQ ID NO: 5); and

4)ATTGATAGAGGCCCTGTTTCATGACATTTTCATGAGTTTCAAT
ATGTTGTTTCAGCATGTTGTGAGGTGACTCTCAGCCCCTTTCCC
ACTGAGATGGACTGTGGTGATGCTGTGAGGGTGTGACTGACA
10 CACCTTCATGTGCCCAAGCATGGGTTTGATCACAGGTCACATG
CAGTTTTTGGCATAGTAAATGTATCATTGTTCTTTTCCTCCCTC
CTAAAGGAAACAGAGGAATCCACCTGTATGAGAGTGCCATGT
AGGGATAAACTTAAAGGACAGATGACACATTGGTCATGTTTCG
TGATAAGGAAA (DHG-1) (SEQ ID NO: 6).

15

The invention also provides SEQ ID NOS: 1-3, 5 and 6 set out above.

In initial studies the gene IHG-2 was assumed to be new.
20 However, as hereinafter demonstrated IHG-2 was identified as being a
formerly unknown part of the gremlin gene. We have found that
mesangial cell gremlin mRNA levels are induced by high glucose,
cyclic mechanical strain and TGF- β 1 *in vitro*, and gremlin mRNA levels
are elevated in the renal cortex of rats with streptozotocin-induced
25 diabetic nephropathy *in vivo*. Gremlin expression was observed in
parallel with induction of bone morphogenetic protein-2 (BMP-2), a
target for gremlin in models of cell differentiation.

Fig. 22 is an autoradiograph of gremlin, fibronectin and GAPDH mRNA levels analysed by Northern Blot as described in Example 8;

5 Fig. 23 is a graph of relative mRNA levels as estimated by Phosphor Imager quantification; and

Fig. 24 is a graphical representation of representative reactions of four independent experiments as described in Example 9.

10 The invention will be further illustrated by the following Examples:

Modes for Carrying Out the Invention

15 Example 1

Identification of mesangial cell genes differentially induced by high glucose.

20 a) Cell culture and streptozotocin-induced diabetic rats

Primary human mesangial cells were cultured as previously reported (Brady, H.R., *et al.* (1992) *Kidney Int.* 42, 480-487 and Denton, M.D., *et al.* (1991) *Am. J. Physiol.* 261, F1071-F1079). Cells (passage 25 7-11) were maintained in medium (Clonetics) containing either 5 mM or 30 mM D-glucose for 7 days. Culture medium was replenished three times during this period to maintain glucose levels in the desired range. To control for the effects of hyperosmolarity, mesangial cells were

Example 8Regulation of mesangial cell gremlin expression by high glucose:
evidence for involvement of TGF- β 1

5

As indicated above, both high ambient glucose concentrations and cyclic mechanical strain provoke TGF- β 1 production by mesangial cells *in vitro* and TGF- β 1 appears to be a major stimulus for mesangial matrix accumulation in diabetic glomeruli *in vivo*. To probe the
10 mechanism by which high glucose triggers gremlin expression, primary human mesangial cells were propagated in 5 mM or 30 mM glucose in the presence and absence of anti-TGF- β 1 neutralising antibody (1 μ g/ml). Treatment of cultures with glucose and anti-TGF- β 1 were as described in Example 1 and Example 4, respectively. To assess the role
15 of TGF- β 1 as a stimulus for gremlin expression, cells were serum restricted for 24 h in MCDB131 and 0.5% FBS and subsequently treated with 10ng/ml TGF- β 1. MCDB131 is a specialised medium for the growth of mesangial cells and is obtained from Clonetics.

20

Initial studies had indicated that TGF- β 1 neutralizing antibody (data not shown) blunted glucose-triggered gremlin expression and therefore the ability of TGF- β 1 to alter gremlin expression was investigated. The results are shown in Figs. 22 and 23.

25

The addition of exogenous human recombinant TGF- β 1 (10 ng/ml, 24 h) to serum restricted (24 h) mesangial cells also augmented

gremlin mRNA levels, suggesting that high glucose enhances gremlin mRNA expression, at least in part, through its ability to stimulate TGF- β 1 expression. In aggregate, these observations suggest the presence of a novel autocrine loop through which TGF- β 1 induces gremlin gene expression and may thereby regulate the activity of mesangial-derived BMPs as hereinafter described.

It was found that gremlin expression in response to high glucose (30 mM, 7 days) was reduced in the presence of anti-TGF- β 1 antibody (data not shown). To further probe the role of TGF- β 1 as a modulator of gremlin expression, mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 h (lane 2). Cells cultured in MCDB131 and 0.5% FBS for 24 h served as a control (lane 1).

Fig. 22 is an autoradiograph of gremlin (1), fibronectin (2) and GAPDH (3) mRNA levels analysed by Northern Blot.

Fig. 23 shows relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 9High glucose stress induces BMP-2, but not BMP-4 expression in
mesangial cells.

As indicated above gremlin is a putative antagonist of BMP-2 and BMP-4. Specifically, gremlin has been recently reported to form heterodimers with BMPs and thereby antagonise BMP signalling (Hsu, D.R., et al. (1998) *supra*). In the present study, RT-PCR was employed as an initial assessment of mesangial cell BMP expression.

As an initial assessment of the relationship between gremlin expression and BMP expression, RNA was isolated from mesangial cells grown for 7 days in either 5mM or 30mM glucose. Following reverse transcription with random primers, a primary PCR of the ORF of BMP-2 was performed. This product, which was undetectable on an ethidium stained agarose gel after 30 cycles, was nested to give a predicted product of 446 bp. PCR analysis with BMP-4 and GAPDH specific primers gave predicted products of 378 bp and 452 bp respectively.

Fig. 24 depicts representative reactions of 4 independent experiments. 10µl of each PCR reaction was run on 1 % ethidium bromide stained agarose gels.

Claims: -

- 5 1. A method for identifying a gene having a role in the presentation of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a gene susceptible to such differential expression and identifying the gene so induced by suppression subtractive hybridisation.
- 10 2. A method according to Claim 1, wherein the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.
- 15 3. A method according to Claim 1 or 2, wherein the concentration of glucose is greater than 5 mM.
4. A method according to any preceding claim, wherein the mesangial cells are subjected to mechanical strain.
- 20 5. A method according to any preceding claim, wherein transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

6. A method according to any one of Claims 1-5, wherein the possibility of differential expression due to hyperosmolarity is excluded.

5 7. A method according to any one of Claims 1-6, wherein the gene so differentially expressed is a gene which includes a sequence selected from:

10 1) SEQ ID NOS: 1-3;

2) SEQ ID NO: 4;

3) SEQ ID NO: 5; and

15 4) SEQ ID NO: 6.

8. Use of a gene identified by a method according to any one of Claims 1-7, as a diagnostic marker for the progression and presentation of diabetic nephropathy.

20

9. Use of a gene identified by a method according to any of Claims 1-7, as an index of disease activity and the rate of progression of diabetic nephropathy.

25 10. Use of a gene identified by a method according to any of Claims 1-7, as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

11. A sequence selected from any one of SEQ ID NOS: 1-3, 5 and 6 according to Claim 7.

5

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference P00-18-PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/IE 00/ 00026	International filing date (day/month/year) 28/02/2000	(Earliest) Priority Date (day/month/year) 26/02/1999
Applicant HIBERGEN LIMITED et al		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IE 00/00026

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOLMES D I ET AL: "Identification of glucose -regulated genes in human mesangial cells by mRNA differential display." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1997 SEP 8) 238 (1) 179-84. , XP000919240 the whole document	1-7
A	DATABASE EMSTS 'Online! EMBL, Heidelberg; Accession Number G38490, 24 June 1998 (1998-06-24) MYERS R.M.: "Human STSs 1998" XP002143063 abstract	12
	--- -/-- ---	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 July 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luzzatto, E

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IE 00/00026

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE EMBL 'Online! EMBL, Heidelberg; Accession Number AA071138, 4 October 1996 (1996-10-04) HILLIER L. ET AL.: "Generation and analysis of 280000 human expressed sequence tags" XP002143064 abstract	12
P,X	--- MURPHY M ET AL: "Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells." JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 FEB 26) 274 (9) 5830-4. , XP002142860 the whole document	1-7
P,X	--- DATABASE EMHUM 'Online! EMBL, Heidelberg; Accession Number AK000553, 22 February 2000 (2000-02-22) SUGANO S. ET AL.: "NEDO human cDNA sequencing project" XP002143065 abstract	12
P,X	--- DATABASE GENESEQ 'Online! Derwent; Accession Number Z52443 (W0-A-9957144), 24 February 2000 (2000-02-24) HILLMAN J.L. ET AL.: "New peptides useful for diagnosis, prevention and treatment of cancer and immune disorders" XP002143066 abstract	12
X	--- DATABASE EMBL 'Online! EMBL, Heidelberg; Accession Number N52279, 18 February 1996 (1996-02-18) HILLIER L. ET AL.: "The WashU-Merck EST project" XP002143067 abstract -----	12

gene susceptible to such differential expression and identifying the gene so induced.

5 Preferably, the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.

10 Further, preferably, the concentration of glucose is greater than 5 mM.

A concentration of 5 mM falls within the normal range of plasma glucose levels in a healthy human subject (4.2 – 6.4 mmol/l).

15 The concentration of glucose used is suitably in the range 5-30 mM. The concentration of 30 mM was chosen as the classic "*in vitro*" model of diabetic nephropathy which induces changes in mesangial function that mimic human disease. This level is also encountered in many diabetics *in vivo*.

20 In one embodiment, the mesangial cells are subjected to mechanical strain.

In a further embodiment, transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

25

Preferably, the differentially expressed gene is identified by suppression subtractive hybridisation.

AAAATTATTTTTTATCTGCTGGCCTT (SEQ ID NO: 2)

.....ATGACACAAATATTAG

GATTTTATTTTTACTATTATCCACCAGCAACAAGATATCAAAC

ACTGGTTCTGTGATTATTTAATGGTGAAAAAGTTGAATAAATC

5 AATTTAGTATACCCATATGTTGGAATATTGAGTCCATTTTTCTT

TTAAAAATCACACTTTGGAATAATTGATGATACTGGCAAATGC

TCAAGCTGAGTGGAAAAATATATAAACATTGTATAGGCGAAT

AATTCCAATCTTGTGCATTCCCTGTGTAAACCTACATACACAA

AAAGAAAAAAGACTGAAAGGAACCATCCACAATGCTTTGATC

10 GGGAAAGACGGAGAAACAAAGTGTTAATTTTCTTAACTATAG

TTTTNGGTGTATTCCAGATTTTCTACAAGTTAATA (IHG-1) (SEQ
ID NO: 3);

GTACTTTGGATTTGGTTAACCTGTTTTCTTCAAGCCTGAGGTTT

15 TATATACAAACTCCCTGAATACTCTTTTTGCCTTGTATCTTCTC

AGCCTCCTAGCCAAGTCCTATGTAATATGGAAAACAAACACT

GCAGACTTGAGATTCAGTTGCCGATCAAGGCTCTGGCATTCTAG

AGAACCCTTGCAACTCGAGAAGCTGTTTTTATTTTCGTTTTTGT

TTGATCCAGTGCTCTCCCATCTAACAACCTAAACAGGAGCCATT

20 TCAAGGCGGGAGATATTTTAAACACCCAAAATGGTTGGGTCT

GATTTTCAAACCTTTTAAACTTCACTACTGATGATTCTGCACG

CTAAGGCGAATTTGGTCCAAACACATAAGTGTGTGTGTTTTGT

ATACACTGTATGACCCCAACCCCAAATCTTTGTATTGTCCACAT

TCTCC (SEQ ID NO: 4);

25

3)AGAAGCAATTTAGGAANCCNACAGNAAANAAATGCTGTTTT

ATAGGAGAGAAAACACGGCACACCAAGGTTAAGTAGTTTGTA

GACGATGTTGAATAGGTTTCAGGTACAGGTCAATGCAGTGATG
AGGAAAGCACCTANGTATACTTGACAGATAGTCCCCTTTGCTT
AACACCCAACTCCTCCACCCTGTGCAGTTTNNCTTGTGCCAGT
GATCACAGGATTCGCTGAGTGAATTACCATAATTGGATTTAAT
5 TCACGAAGGGGATGTTTTTC (IHG-3) (SEQ ID NO: 5); and

4)ATTGATAGAGGCCCTGTTTCATGACATTTTCATGAGTTTCAAT
ATGTTGTTTCAGCATGTTGTGAGGTGACTCTCAGCCCCCTTTCCC
ACTGAGATGGACTGTGGTGATGCTGTGAGGGTGTGACTGACA
10 CACCTTCATGTGCCCAAGCATGGGTTTGATCACAGGTCACATG
CAGTTTTTGGCATAGTAAATGTATCATTGTTCTTTTCCTCCCTC
CTAAAGGAAACAGAGGAATCCACCTGTATGAGAGTGCCATGT
AGGGATAAACTTAAAGGACAGATGACACATTGGTCATGTTTCG
TGATAAGGAAA (DHG-1) (SEQ ID NO: 6).

15

The invention also provides genes containing sequences 1-3, 5 and 6 set out above.

In initial studies the gene IHG-2 was assumed to be new.
20 However, as hereinafter demonstrated IHG-2 was identified as being a
formerly unknown part of the gremlin gene. We have found that
mesangial cell gremlin mRNA levels are induced by high glucose,
cyclic mechanical strain and TGF- β 1 *in vitro*, and gremlin mRNA levels
are elevated in the renal cortex of rats with streptozotocin-induced
25 diabetic nephropathy *in vivo*. Gremlin expression was observed in
parallel with induction of bone morphogenetic protein-2 (BMP-2), a
target for gremlin in models of cell differentiation.

Fig. 22 is an autoradiograph of gremlin, fibronectin and GDAPH mRNA levels analysed by Northern Blot as described in Example 8;

Fig. 23 is a graph of relative mRNA levels as estimated by
5 Phosphor Imager quantification; and

Fig. 24 is a graphical representation of representative reactions of four independent experiments as described in Example 9.

10 The invention will be further illustrated by the following Examples:

Modes for Carrying Out the Invention

15 Example 1

Identification of mesangial cell genes differentially induced by high glucose.

20 a) Cell culture and streptozotocin-induced diabetic rats

Primary human mesangial cells were cultured as previously reported (Brady, H.R., *et al.* (1992) *Kidney Int.* 42, 480-487 and Denton, M.D., *et al.* (1991) *Am. J. Physiol.* 261, F1071-F1079). Cells (passage
25 7-11) were maintained in medium (Clonetics) containing either 5 mM or 30 mM D-glucose for 7 days. Culture medium was replenished three times during this period to maintain glucose levels in the desired range. To control for the effects of hyperosmolarity, mesangial cells were

Example 8Regulation of mesangial cell gremlin expression by high glucose:
evidence for involvement of TGF- β 1

5

As indicated above, both high ambient glucose concentrations and cyclic mechanical strain provoke TGF- β 1 production by mesangial cells *in vitro* and TGF- β 1 appears to be a major stimulus for mesangial matrix accumulation in diabetic glomeruli *in vivo*. To probe the
10 mechanism by which high glucose triggers gremlin expression, primary human mesangial cells were propagated in 5 mM or 30 mM glucose in the presence and absence of anti-TGF- β 1 neutralising antibody (1 μ g/ml). Treatment of cultures with glucose and anti-TGF- β 1 were as described in Example 1 and Example 4, respectively. To assess the role
15 of TGF- β 1 as a stimulus for gremlin expression, cells were serum restricted for 24 h in MCDB131 and 0.5% FBS and subsequently treated with 10ng/ml TGF- β 1. MCDB131 is a specialised medium for the growth of mesangial cells and is obtained from Clonetics.

20

Initial studies had indicated that TGF- β 1 neutralizing antibody (data not shown) blunted glucose-triggered gremlin expression and therefore the ability of TGF- β 1 to alter gremlin expression was investigated. The results are shown in Figs. 22 and 23.

25

The addition of exogenous human recombinant TGF- β 1 (10 ng/ml, 24 h) to serum restricted (24 h) mesangial cells also augmented

gremlin mRNA levels, suggesting that high glucose enhances gremlin mRNA expression, at least in part, through its ability to stimulate TGF- β 1 expression. In aggregate, these observations suggest the presence of a novel autocrine loop through which TGF- β 1 induces gremlin gene expression and may thereby regulate the activity of mesangial-derived BMPs as hereinafter described.

It was found that gremlin expression in response to high glucose (30 mM, 7 days) was reduced in the presence of anti-TGF- β 1 antibody (data not shown). To further probe the role of TGF- β 1 as a modulator of gremlin expression, mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 h (lane 2). Cells cultured in MCDB131 and 0.5% FBS for 24 h served as a control (lane 1).

Fig. 22 is an autoradiograph of gremlin (1), fibronectin (2) and GAPDH (3) mRNA levels analysed by Northern Blot.

Fig. 23 shows relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 9High glucose stress induces BMP-2, but not BMP-4 expression in mesangial cells.

As indicated above gremlin is a putative antagonist of BMP-2 and BMP-4. Specifically, gremlin has been recently reported to form heterodimers with BMPs and thereby antagonise BMP signalling (Hsu, D.R., et al. (1998) *supra*). In the present study, RT-PCR was employed as an initial assessment of mesangial cell BMP expression.

As an initial assessment of the relationship between gremlin expression and BMP expression, RNA was isolated from mesangial cells grown for 7 days in either 5mM or 30mM glucose. Following reverse transcription with random primers, a primary PCR of the ORF of BMP-2 was performed. This product, which was undetectable on an ethidium stained agarose gel after 30 cycles, was nested to give a predicted product of 446 bp. PCR analysis with BMP-4 and GAPDH specific primers gave predicted products of 378 bp and 452 bp respectively.

Fig. 24 depicts representative reactions of 4 independent experiments. 10uL of each PCR reaction was run on 1 % ethidium bromide stained agarose gels.

Claims: -

1. A method for identifying a gene having a role in the presentation
5 of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a gene susceptible to such differential expression and identifying the gene so induced.
- 10 2. A method according to Claim 1, wherein the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.
- 15 3. A method according to Claim 1 or 2, wherein the concentration of glucose is greater than 5 mM.
4. A method according to any preceding claim, wherein the mesangial cells are subjected to mechanical strain.
- 20 5. A method according to any preceding claim, wherein transforming growth factor β 1 (TGF- β 1) is added to the culture medium.
- 25 6. A method according to any preceding claim, wherein the differentially expressed gene is identified by suppression subtractive hybridisation.

7. A method according to any one of Claims 1-6, wherein the possibility of differential expression due to hyperosmolarity is excluded.

5 8. A method according to any one of Claims 1-7, wherein the gene so differentially expressed is a gene which includes a sequence selected from:

1) SEQ ID NOS: 1-3;

10 2) SEQ ID NO: 4;

3) SEQ ID NO: 5; and

15 4) SEQ ID NO: 6.

9. Use of a gene identified by a method according to any one of Claims 1-8, as a diagnostic marker for the progression and presentation of diabetic nephropathy.

20 10. Use of a gene identified by a method according to any of Claims 1-8, as an index of disease activity and the rate of progression of diabetic nephropathy.

25 11. Use of a gene identified by a method according to any of Claims 1-8, as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

12. A gene containing a sequence selected from any one of sequences 1-3, 5 and 6 according to Claim 8.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/50637 (43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/IE00/00026 (22) International Filing Date: 28 February 2000 (28.02.00) (30) Priority Data: 990157 26 February 1999 (26.02.99) IE (71) Applicants (for all designated States except US): HIBERGEN LIMITED [IE/IE]; Cork Airport Business Park, Kinsale Road, County Cork (IE). UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN [IE/IE]; Belfield, Dublin 4 (IE). (72) Inventors; and (75) Inventors/Applicants (for US only): BRADY, Hugh, Redmond [IE/IE]; "Aspen", Violet Hill, Killiney, County Dublin (IE). GODSON, Catherine, Mary [IE/IE]; 12 Yalc, Ardilea, Dublin 14 (IE). MARTIN, Finian, Mary [IE/IE]; 104 Mount Anville Road, Goatstown, Dublin 14 (IE). (74) Agent: ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IDENTIFICATION OF GENES HAVING A ROLE IN THE PRESENTATION OF DIABETIC NEPHROPATHY		
(57) Abstract <p>A method for identifying a gene having a role in the presentation of diabetic nephropathy comprises culturing mesangial cells in the presence of a concentration of glucose sufficient to induce differential expression, especially up-regulation, of a gene susceptible to such differential expression and identifying the gene so induced. The cells are also optionally subjected to mechanical strain and/or TGF-β1 can be added to the culture medium. The differentially expressed genes can be identified by suppression subtractive hybridisation. The method has resulted in the identification of novel genes which play a role in the presentation of diabetic nephropathy. The genes can be used as diagnostic markers for diabetic nephropathy and as the basis of drug development programmes.</p>		

Description

Identification of genes having a role in the presentation of diabetic nephropathy.

5

Technical Field

This invention relates to the characterisation and identification of genes which play a role in diabetes, more particularly in the onset and progression of diabetic nephropathy and to the use of genes so characterised and/or identified as diagnostic markers for diabetic nephropathy and as the basis of drug development programmes.

10

Background Art

15

Between 2-5% of the population develops diabetes mellitus and 20-30% of diabetics develop diabetic nephropathy. The latter accounts for over 30 % of end-stage renal failure (E.S.R.F.) requiring dialysis or transplantation in western society. The pathological hallmark of diabetic nephropathy is glomerulosclerosis due to accumulation of extracellular matrix proteins in the glomerular mesangium. Mesangial matrix accumulation reflects both increased synthesis and decreased degradation of extracellular matrix (ECM) components, and correlates with the clinical onset of proteinuria, hypertension and progressive kidney failure. Hyperglycaemia is a major stimulus for mesangial cell matrix production in diabetic nephropathy. The mechanisms by which hyperglycaemia perturb mesangial cell function are still being

20

25

appreciated and include direct effects of high extracellular glucose levels and indirect effects transduced through alterations in glomerular haemodynamics and through the actions of advanced glycosylation end products.

5

Propagation of mesangial cells under conditions of high ambient glucose has proved a useful *in vitro* model with which to probe the molecular basis for mesangial matrix accumulation in diabetes, attributable to hyperglycaemia. Specifically, exposure of cultured mesangial cells to high glucose stimulates *de novo* synthesis of ECM components, such as type IV collagen, fibronectin and laminin, and other products that are accumulated *in vivo* (Ayo, S.H., *et al.* (1990) *Am.J. Pathol.* 136, 1339-1348; Wahab, N.A., *et al.* (1996) *Biochem. J.* 316, 985-992; and Ayo, S.H., *et al.* (1991) *Am. J. Physiol.* 260, F185-F191).

15

In view of the high morbidity and mortality rate from diabetic nephropathy in diabetics there is a need to identify stimuli which affect the onset and progression of diabetic nephropathy with the aim of preventing such onset or inhibiting or limiting the progression thereof.

20

Disclosure of Invention

25

The invention provides a method for identifying a gene having a role in the presentation of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a

gene susceptible to such differential expression and identifying the gene so induced.

5 Preferably, the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.

10 Further, preferably, the concentration of glucose is greater than 5 mM.

A concentration of 5 mM falls within the normal range of plasma glucose levels in a healthy human subject (4.2 – 6.4 mmol/l).

15 The concentration of glucose used is suitably in the range 5-30 mM. The concentration of 30 mM was chosen as the classic “*in vitro*” model of diabetic nephropathy which induces changes in mesangial function that mimic human disease. This level is also encountered in many diabetics *in vivo*.

20 In one embodiment, the mesangial cells are subjected to mechanical strain.

In a further embodiment, transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

25

Preferably, the differentially expressed gene is identified by suppression subtractive hybridisation.

Suppression subtractive hybridisation (SSH) is a method based on suppressive PCR that allows creation of subtracted cDNA libraries for the identification of genes differentially expressed in response to an experimental stimulus (Gurskaya, N.G., *et al.* (1996) *Anal. Biochem.* 240, 90-97). SSH differs from earlier subtractive methods by including a normalisation step that equalises for relative abundance of cDNAs within a target population. This modification should enhance the probability of identifying increased expression of low abundance transcripts, and represents a potential advantage over other methods for identifying differentially regulated genes such as differential display-PCR (DD-PCR) (Liang, P., and Pardee, A.B. (1992) *Science* 257, 967-97) and cDNA-representation difference analysis (Hubank, M., and Schatz, D.G., (1994) *Nucleic Acid Res.* 22, 5640-5648).

To date we have used SSH to identify 150 genes differentially induced when human mesangial cells were exposed to high extracellular glucose (defined herein as 30 mM versus 5 mM) *in vitro*. These genes included:

(a) known regulators of mesangial cell activation in diabetic nephropathy, namely fibronectin, caldesmon, thrombospondin and plasminogen activator inhibitor-1;

(b) novel genes; and

(c) genes whose induction by high glucose has not previously been reported as hereinafter described.

Prominent among the latter were genes encoding cytoskeleton-associated proteins and connective tissue growth factor (CTGF), a
5 modulator of fibroblast matrix production. We have also demonstrated elevated CTGF mRNA levels in glomeruli of rats with streptozotocin-induced diabetic nephropathy.

10 In one aspect of the invention, the possibility of differential expression due to hyperosmolarity is excluded.

Hyperosmolarity is, however, a component of diabetic nephropathy and thus hyperosmolarity may represent a mechanism
15 through which high glucose induces differential expression of certain genes having a role in the presentation of the disease.

For example, we have shown that mannitol provoked less mesangial cell CTGF expression *in vitro* than high glucose, excluding
20 hyperosmolarity as the key stimulus.

High glucose also stimulated expression of transforming growth factor $\beta 1$ (TGF- $\beta 1$) and addition of TGF- $\beta 1$ to mesangial cells triggered CTGF expression. Anti-TGF- $\beta 1$ antibody blunted CTGF expression
25 induced by high glucose. Together, these data suggest that (1) high glucose stimulates mesangial CTGF expression by TGF $\beta 1$ -dependent

and independent pathways, and (2) CTGF may be a mediator of TGF- β 1-driven matrix production within a diabetic milieu.

CTGF may therefore be an attractive target for design of novel anti-sclerotic therapies for diabetic glomerulosclerosis.

CTGF derived from mesangial cells is a potential stimulus for increased synthesis of ECM proteins and mesangial expansion in diabetic nephropathy. The mechanisms by which high glucose triggers mesangial cell CTGF and, indeed, TGF- β , mRNA expression remain to be defined. Possible upstream triggers of CTGF transcription in response to high glucose include *de novo* synthesis of diacylglycerol (DAG) and subsequent activation of protein kinase C (PKC) (DeRubertis, F.R., and Craven, P., (1994) *Diabetes* 43, 1-8 and Fumo P., *et al.* (1994) *Am. J. Physiol.* 267, F632-F638), non-enzymatic glycation end-products (Brownlee, M., *et al.* (1984) *Ann. Intern. Med* 101, 527-537 and Cohen, M.P., and Ziyadeh, F.N. (1994) *Kidney Int.* 45, 475-484) increased activity of the polyol pathway and disordered myoinositol metabolism (Goldfarb, S., *et al.* (1991) *Diabetes* 40, 465-471 1991) or through the recruitment of locally generated growth factors such as TGF- β 1 and other mediators. (Sharma K., and Ziyadeh, F.N., (1995) *Diabetes* 44, 1139-1146).

TGF- β 1 has been implicated as the key mediator of extracellular matrix accumulation in diabetic nephropathy and other chronic renal disease. Several studies have reported increased expression of TGF- β 1 in renal glomeruli in human and experimental models of diabetes (Park,

I., *et al.* (1997) *Diabetes* 46, 473-480; Sharma, K., (1996) *Diabetes* 45, 522-530). Short term administration of TGF- β 1 neutralising antibodies attenuates overexpression of mRNAs encoding matrix components and glomerulosclerosis in the STZ mouse model of diabetes (Park, I., *et al.* 5 (1997) *Diabetes* 46, 473-480). CTGF shares some of the biological actions of TGF- β 1 such as stimulation of cell proliferation and extracellular matrix protein synthesis in fibroblasts. When considered in this context, the results described herein suggest that TGF- β 1 may promote mesangial matrix production, in part, by inducing CTGF 10 synthesis. TGF- β 1 has a complex profile of biological activities that includes pro-inflammatory, pro-fibrotic and anti-inflammatory effects. By targeting CTGF it may be possible to attenuate the sclerosis-inducing effects of TGF- β 1 while preserving its more desirable anti-inflammatory activities.

15 Novel genes identified by the method according to the invention are identified herein as IHG (*Increased in High Glucose*) and DHG (*Down in High Glucose*) and are represented by genes which include the following sequences 1, 3 and 4:

20 1) TTGGAATAGTTCTTGCTTTATAAAAATAGTACTGCGATTAAA
AAAAAAGCACTTCTGCCAAAGGAACCATGTTCCAACACCGCA
AACAAGGTGTTCTGCTTAAACAGAGTAAGATACACCACCCCC
ATCCATCCCTTCCTTCCCTGTTCCCCTCCCAACTTGAGTTGTGT
25 CATTCGCACCAGTGTCCTGGGTGGTAGGGATGCTACAGCCAC
CTAAGGCAAGGAGCCCTGGGAGGTGGGAGGGCTTGCATGGTT
AAGCACACCAGAACTGAAGCGCAAAAGGGTCAGCTGTCTTCA

TCTAGAATCTCTGGATGTTCCCTTCCAGAAAGCATCCCCGATGA
TATCGCAGTGCAAGGGGCACTGGCTTTGTCCTGGTCCGGGGTCAC
TGCCATCTTTTTTTCCTTCCATTTCTGTTGGCAGCTTAATTTCTTT
TGTCATCACTTCATCCACCTTCTGCCATATCAACACAGTCCCTT
5 TCCTATACATCGGCAGCTCATTATTATAGTTGATGTTGAATTC
AGAAAACAAAATCTCATTCTTGTCTGCTGNAAGAGTTCCCTGT
AATCTCCCTTGGGCTTGTACTGGTGTTAGTCCAGATTGTTG
(SEQ ID NO: 1)

.....
10GGTCCTTTAA
AGTCTGGTTGCTGGGATACACCACGACTCTTCCGGTCAAAGCC
TGGGGGATACAGAAGGGGCTRGTCCTCAAAGTAATCCCGCCA
ATAAAACAYATAGCTGGAGGCAAACCTGGGAGGGYCACGTGAGT
CATGAACTTTACTGGCTCTTCTTTTAAACCAATTGGTTTTCCGC
15 TTGWACACAAAGCTGTACTCATCACTCTGTCCATAACGCGAT
CACAATATCCTCTAGTTCTTCCATCACAGTCTGCGCACATTTG
GTCATCAGCTGGAGAGCACGGCTGTCATTGGGTTTTGCAAAGT
TGTGCTTCTCAGCAAACCGATGGAAATTCCGGCCGTCCAGCCG
NACTACCACCCAGCAGTGTGCCAGGCAGGTGTCGTCAGCCTC
20 GAAGTCCCTCACGTACTCGAACTTGCTTTTTTGCCATGGTCGCC
CCCAATCTCAGGTACCGTCTCAGAGTGATGGAAATGGTGGCC
AAGGAATCGTGAACCTTAACTTTACAGGCGCCCCACATTCTAC
ACGCGGAAAGGAAAGGGCCAGATAGCCCCGCCCCGGAAGTG
TTCTCTTCGTGGCTACTCTAGCCGTAGGGCGGTCATAGTCTCT
25 CTCGSCTCTCCCTGKAGTTCTTAAMCYCCAGGGAAARAGGA
TGGAGGTTTAGGTTCCCTCCGTTAGCACCTTCCACGCTTGCTTCT
TCCTCCTCCCGGTCTGCGGCAAATCAGTCTCACGAGGTTTTTA

AAAATTATTTTTTATCTGCTGGCCTT (SEQ ID NO: 2)

.....ATGACACAAATATTAG

GATTTTATTTTTACTATTATCCACCAGCAACAAGATATCAAAC

ACTGGTTCTGTGATTATTTAATGGTGAAAAAGTTGAATAAATC

5 AATTTAGTATACCCATATGTTGGAATATTGAGTCCATTTTTCTT

TTAAAAATCACACTTTGGAATAATTGATGATACTGGCAAATGC

TCAAGCTGAGTGGAAAAATATATAAACATTGTATAGGCGAAT

AATTCCAATCTTGTGCATTCCCTGTGTAAACCTACATACACAA

AAAGAAAAAAGACTGAAAGGAACCATCCACAATGCTTTGATC

10 GGGAAAGACGGAGAAACAAAGTGTTAATTTTCTTAACTATAG

TTTTNGGTGTATTCCAGATTTTCTACAAGTTAATA (IHG-1) (SEQ
ID NO: 3);

GTACTTTGGATTTGGTTAACCTGTTTTCTTCAAGCCTGAGGTTT

15 TATATACAAACTCCCTGAATACTCTTTTTGCCTTGTATCTTCTC

AGCCTCCTAGCCAAGTCCTATGTAATATGGAAAACAAACACT

GCAGACTTGAGATTCAGTTGCCGATCAAGGCTCTGGCATTTCAG

AGAACCCTTGCAACTCGAGAAGCTGTTTTTATTTTCGTTTTTGTT

TTGATCCAGTGCTCTCCCATCTAACAATAAACAGGAGCCATT

20 TCAAGGCGGGAGATATTTTAAACACCCAAAATGGTTGGGTCT

GATTTTCAAACCTTTTAAACTTCACTACTGATGATTCTGCACG

CTAAGGCGAATTTGGTCCAAACACATAAGTGTGTGTGTTTTGT

ATACACTGTATGACCCCAACCCCAAATCTTTGTATTGTCCACAT

TCTCC (SEQ ID NO: 4);

25

3)AGAAGCAATTTAGGAANCCNACAGNAAANAAATGCTGTTTT

ATAGGAGAGAAAACACGGCACACCAAGGTTAAGTAGTTTGTA

GACGATGTTGAATAGGTTCAGGTACAGGTCAATGCAGTGATG
AGGAAAGCACCTANGTATACTTGACAGATAGTCCCCTTTGCTT
AACACCCAACTCCTCCACCCTGTGCAGTTTNNCTTGTGCCAGT
GATCACAGGATTCGCTGAGTGAATTACCATAATTGGATTTAAT
5 TCACGAAGGGGATGTTTTTC (IHG-3) (SEQ ID NO: 5); and

4)ATTGATAGAGGCCCTGTTTCATGACATTTTCATGAGTTTCAAT
ATGTTGTTTCAGCATGTTGTGAGGTGACTCTCAGCCCCTTTCCC
ACTGAGATGGACTGTGGTGATGCTGTGAGGGTGTGACTGACA
10 CACCTTCATGTGCCCAAGCATGGGTTTGATCACAGGTCACATG
CAGTTTTTGGCATAGTAAATGTATCATTGTTCTTTTCCTCCCTC
CTAAAGGAAACAGAGGAATCCACCTGTATGAGAGTGCCATGT
AGGGATAAACTTAAAGGACAGATGACACATTGGTCATGTTTCG
TGATAAGGAAA (DHG-1) (SEQ ID NO: 6).

15

The invention also provides genes containing sequences 1-3, 5
and 6 set out above.

In initial studies the gene IHG-2 was assumed to be new.

20 However, as hereinafter demonstrated IHG-2 was identified as being a
formerly unknown part of the gremlin gene. We have found that
mesangial cell gremlin mRNA levels are induced by high glucose,
cyclic mechanical strain and TGF- β 1 *in vitro*, and gremlin mRNA levels
are elevated in the renal cortex of rats with streptozotocin-induced
25 diabetic nephropathy *in vivo*. Gremlin expression was observed in
parallel with induction of bone morphogenetic protein-2 (BMP-2), a
target for gremlin in models of cell differentiation.

Gremlin, together with DAN and cerberus, are members of the cysteine knot super-family of proteins that have recently been shown to play important roles in limb development and neural crest cell differentiation (Hsu, D.R., *et al.* (1998) *Mol. Cell.* 1, 673-83; Zuniga, A., *et al.* (1999) *Nature* 401, 598-602). Of potential interest in the context of diabetic nephropathy, gremlin is a putative inhibitor of BMP-2 in models of neural crest cell differentiation. BMP-2 has recently been reported to have antiproliferative effects on mesangial cells.

The following Examples show that (a) IHG-2 is part of gremlin, (b) gremlin is expressed in diabetic nephropathy *in vivo*, (c) both glycemic and mechanical strain stimulate mesangial cell gremlin expression *in vitro*, (d) high glucose induces gremlin, in part, through TGF β -mediated pathways, and (e) gremlin is a potential endogenous antagonist of BMPs within a diabetic glomerular milieu.

The invention also provides use of a gene identified by the method according to the invention:

1) as a diagnostic marker for the progression and presentation of diabetic nephropathy;

2) as an index of disease activity and the rate of progression of diabetic nephropathy; and

3) as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

Thus, it will be appreciated that early diagnosis of diabetic nephropathy based on diagnostic markers identified in accordance with the invention can be used in conjunction with aggressive therapies to prevent full blown development of diabetic nephropathy.

The level of expression of genes identified in accordance with the invention could correlate with the degree of disease progression.

Furthermore, genes identified in accordance with the invention can represent novel therapeutic targets for drug development programmes. Once it has been established that a given gene has a designated role in the pathophysiology of diabetic nephropathy, the development of new therapeutic agents (such as, for example, small molecules, recombinant inhibitors and receptor antagonists) could be designed to inhibit expression of these genes and, thereby, prevent the development of diabetic nephropathy.

Genes identified in accordance with the invention can also be used as a clinical index of progressive renal sclerosis and scarring, as a guide to the response of progressive diabetic nephropathy to therapy and also as markers of the prevention or development thereof.

It is possible to generate mouse knock-out (k/o) models for genes identified in accordance with the invention and to generate

diabetic k/o mouse models, (for example by treatment with streptozotocin) and determine if onset of diabetic nephropathy is inhibited, reduced or delayed. Thus one can determine if a given knock-out gene has a definite role in the progression and development of diabetic nephropathy.

Brief Description of Drawings

Fig. 1 is an autoradiograph of CTGF levels analysed by Northern Blot as described in Example 2;

Fig. 2 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 2;

Fig. 3 is a 2 % agarose gel showing ethidium-stained PCR products as described in Example 2;

Fig. 4 is a nucleotide sequence alignment of the rat CTGF transcript and the mouse CTGF homologue fisp 12 as described in Example 3;

Fig. 5 is an amino acid sequence alignment of the rat CTGF transcript and the mouse CTGF homologue fisp 12 as described in Example 3;

Fig. 6 is a 2 % agarose gel showing ethidium-stained PCR products as described in Example 3;

Fig. 7 is an autoradiograph of CTGF levels in the presence of TGF- β 1 and TGF- β 1 neutralising antibodies analysed by Northern Blot as described in Example 4;

5

Fig. 8 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 4;

Fig. 9 is an autoradiograph of CTGF levels in the presence of varying amounts of glucose and TGF- β 1 neutralising antibodies analysed by Northern Blot as described in Example 4;

10

Fig. 10 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 4;

15

Fig. 11 is an autoradiograph of CTGF levels in the presence of varying amounts of glucose and PKC inhibitor GF102903X analysed by Northern Blot as described in Example 4;

Fig. 12 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 4;.

20

Fig. 13 is a graphical representation of a BLAST output from the EST database as described in Example 6;

25

Fig. 14 is a graphical representation of the alignment of human gremlin and rat drm when compared using the BLAST algorithm as described in Example 6;

5 Fig. 15 is the sequence of mesangial cell gremlin cDNA;

Fig. 16 is an autoradiograph of IHG-2, gremlin, fibronectin and GAPDH mRNA levels analysed by Northern Blot as described in Example 7;

10

Fig. 17 is a graph of relative mRNA levels as estimated by Phosphor Imager quantification as described in Example 7;

15 Fig. 18 is an autoradiograph of gremlin, fibronectin and GAPDH mRNA analysed by Northern Blot as described in Example 7;

Fig. 19 is a further graph of relative mRNA levels as estimated by Phosphor Imager quantification as described in Example 7;

20 Fig. 20 is an autoradiograph of gremlin mRNA levels in the kidney cortex of a STZ-diabetic rat and an age matched control analysed by Northern Blot as described in Example 7;

25 Fig. 21 is a further graph of relative mRNA levels as estimated by Phosphor Imager quantification as described in Example 7;

Fig. 22 is an autoradiograph of gremlin, fibronectin and GDAPH mRNA levels analysed by Northern Blot as described in Example 8;

Fig. 23 is a graph of relative mRNA levels as estimated by
5 Phosphor Imager quantification; and

Fig. 24 is a graphical representation of representative reactions of four independent experiments as described in Example 9.

10 The invention will be further illustrated by the following Examples:

Modes for Carrying Out the Invention

15 Example 1

Identification of mesangial cell genes differentially induced by high glucose.

20 a) Cell culture and streptozotocin-induced diabetic rats

Primary human mesangial cells were cultured as previously reported (Brady, H.R., *et al.* (1992) *Kidney Int.* 42, 480-487 and Denton, M.D., *et al.* (1991) *Am. J. Physiol.* 261, F1071-F1079). Cells (passage
25 7-11) were maintained in medium (Clonetics) containing either 5 mM or 30 mM D-glucose for 7 days. Culture medium was replenished three times during this period to maintain glucose levels in the desired range. To control for the effects of hyperosmolarity, mesangial cells were

cultured in media containing 5 mM glucose supplemented with 25 mM mannitol.

Male Munich-Wistar rats (260-290 g, Simonsen Laboratories) were rendered diabetic by treatment with streptozotocin (STZ; Sigma), 50 g/kg, intravenously as described previously (Zatz, R., *et al.* (1985). *Proc. Natl. Acad. Sci. USA.* 82, 5963-5967). At months 2 and 4 after induction of diabetic nephropathy (DN), rats were anaesthetized with intraperitoneal injection of pentobarbital (50 mg/kg), and the right kidney was excised and weighed immediately. Glomeruli were isolated from renal cortex by the standard sieving method (Brady, H.R. *et al.* (1992) and Denton, M.D. *et al.* (1991) *supra*). Glomerular isolation was completed within 20 minutes of removing the kidney. RNA extraction proceeded immediately thereafter.

b) RNA isolation

Polyadenylated RNA was isolated from mesangial cells using the Microfast Track (Microfast Track is a Trade Mark) kit (Invitrogen). Total RNA was isolated from glomeruli using RNazol solution (TEL-test Inc.).

c) Suppression subtractive hybridisation (SSH)

SSH was performed with the PCR-SELECT cDNA subtraction kit (Clontech) as directed by the manufacturer with the modification that a four-fold greater than recommended amount of driver cDNA was

added to the second hybridisation. Starting material consisted of 2 µg of mesangial cell mRNA cultured in 30 mM D-glucose for 7 days as “tester” and 2 µg of mesangial cell mRNA cultured in 5 mM D-glucose for 7 days as “driver”. Thirty primary PCR cycles and 12 secondary
5 PCR cycles were performed.

d) Cloning and sequencing of cDNAs

PCR products generated by SSH were subcloned into the PCR
10 2.1 vector using the original TA cloning kit (Invitrogen). Subcloned cDNAs were isolated by colony PCR amplification. Sequencing was performed using an automated ABI 370A DNA sequencing system. Sequence reactions were carried out with the ABI prism dye terminator cycle sequencing ready reaction kit (Perkin Elmer). The sequences
15 obtained were compared against GenBank/EMBL and Expressed Sequence Tag (EST) databases using BLAST searches.

SSH analysis suggested differential induction of 16 mRNAs in primary cultures of human mesangial cells propagated for 7 days in 30
20 mM glucose. Northern Blots performed using formaldehyde denaturation according to standard protocols and quantitated using a Phosphor Imager (Biorad) confirmed differential expression of fifteen of the sixteen subcloned fragments as indicated in Table 1.

25 In Table 1 ^a refers to the sequence identity based on comparisons with the Genbank/EMBL database;

^b refers to an estimate of the size (kb) of the mRNA identified by Northern Blot analysis; and

^c refers to the differential expression of each gene based on Northern Blot analysis of primary human mesangial cells cultured under indicated conditions relative to expression in cells cultured in 5 mM glucose. Values were obtained by Phosphor-Imaging and were normalised by comparison with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (*, detected in mesangial cells cultured in 5 mM glucose + 25 mM mannitol and 30 mM glucose, but not in 5 mM glucose, fold expression is degree of expression relative to that found in 5 mM glucose).

Table 1

Summary of cDNAs identified by SSH as being induced in mesangial cells cultured in high glucose.

5

<u>Gene^a</u>	<u>mRNA^b</u>	<u>Differential Expression^c</u>	
		<i>30mM glucose</i>	<i>25mM mannitol+ 5mM glucose</i>
<i>Extracellular Matrix Proteins</i>			
Fibronectin	7.0	2.1-fold	1.5-fold
Thrombospondin	6.0	7.0-fold	8.0-fold
<i>Actin-Binding Proteins</i>			
MRLC	0.9	3.9-fold	1.6-fold
T-plastin	1.2	4.2-fold	1.8-fold
Caldesmon	3.6	3.3-fold	2.8-fold
Profilin	1.0	2.2-fold	2.3-fold
CAP	2.6	1.5-fold	1.7-fold
ARP3	2.5	2.0-fold	1.0-fold
<i>Growth Factors</i>			
CTGF	2.4	3.0-fold	1.5-fold
<i>Others</i>			
PAI-1	2.0	1.2-fold	1.0-fold
	3.0	3.9-fold	2.0-fold
RBM3	1.5	1.8-fold	1.4-fold
Ubiquitin	3.0	2.3-fold	1.7-fold
TCTP	0.8	4.3-fold	2.5-fold
IHG-1	3.4	*	*
IHG-2	2.5	2.0-fold	2.0-fold

Sequence analysis revealed induction of four genes implicated previously in the pathogenesis of diabetic nephropathy: fibronectin, caldesmon, PAI-1, and thrombospondin. Of eleven other cDNA fragments, one encoded a novel gene, designated herein as IHG-1 and
5 ten encoded known genes, including IHG-2 as hereinafter described, whose induction by high glucose had not been reported previously. Prominent among the latter genes were connective tissue growth factor (CTGF) and several cytoskeleton-associated proteins, namely profilin, caldesmon, adenyl cyclase-associated protein (CAP), actin-related
10 protein-3 (ARP3), T-plastin, and myosin regulatory light chain (MRLC). Subsequent studies focused on induction of CTGF, a regulator of matrix production in several model systems as described in Examples 2 and 3. The prominence of genes encoding multiple actin-binding proteins is also noteworthy, given recent reports implicating F-
15 actin disassembly in the pathogenesis of mesangial cell dysfunction and glomerular hypertension in diabetic nephropathy (Zhou, X., *et al.* (1995) *Lab. Invest.* 73, 372-383 and Zhou, X. Lai, *et al.* (1997) *Kidney Int.* 51, 1797-1808). The induction of profilin expression is particularly interesting given its role as a regulator of actin polymerization under
20 conditions of cell stress (Sohn, R.H. and Goldschmidt-Clermont, P.J. (1994) *Bioessays* 16, 465-472).

Within a diabetic milieu, high glucose levels may perturb cellular function through glucose-specific actions or by increasing the
25 osmolarity of extracellular fluids. The role of hyperosmolarity as a mediator of gene induction by high glucose was assessed by comparing mRNA levels, as determined by Northern Blot, in cells cultured in either

30 mM glucose or in 5 mM glucose supplemented with 25 mM mannitol. High glucose was more effective than high osmolarity at inducing expression of CTGF, myosin regulatory light chain (MRLC), actin related protein 3 (ARP3), T-plastin and translationally controlled tumor protein (TCTP). High glucose and mannitol-induced hyperosmolarity afforded equivalent induction of the other products.

Example 2

CTGF expression in mesangial cells cultured in high glucose.

a) Influence of high ambient glucose on CTGF mRNA levels in human mesangial cells.

CTGF, is a 38kD cysteine-rich secreted peptide known to modulate ECM production in some extrarenal cell types. In Example 1, SSH analysis identified a cDNA fragment of 250 bp which was identical to bases 814-1061 of the human CTGF cDNA. Induction of CTGF mRNA expression in primary human mesangial cells cultured in high glucose was investigated by Northern Blotting as shown in Fig. 1.

In Fig. 1 the lanes represent the following:

Lane 1: RNA from mesangial cells exposed to 5 mM glucose;

Lane 2: RNA from mesangial cells exposed to 5 mM glucose and 25 mM mannitol;

Lane 3: RNA from mesangial cells exposed to 30 mM glucose for seven days.

5 A 2.4 kb band was detected following hybridisation with the CTGF probe. The relative amounts of CTGF mRNA as estimated by Phosphor Imager quantification are indicated in Fig. 2. All of the values were normalised to GAPDH levels and the results are representative of three independent experiments.

10

The results indicate that CTGF mRNA expression was between 2.5-3.3-fold higher in mesangial cells cultured in 30 mM glucose as compared with 5 mM glucose.

15

b) Effect of CTGF on mesangial cell matrix production.

To investigate the direct effects of CTGF up-regulation on matrix production, in particular the effect on collagens I and IV and fibronectin, mesangial cells were incubated with recombinant CTGF protein.

20

Mesangial cells were serum starved for 24 hr in RPMI 1640 medium supplemented with 0.5 % fetal bovine serum (FBS) and then exposed to rhCTGF (8 ng/ml) (a generous gift from Dr. Gary Grotendorst) for 24 hr (Kreisberg, J.I. and Ayo, S.H. (1993). *Kidney Int.* 43, 109-113). Total RNA was extracted and chromosomal DNA was removed using DNase 1 (Gibco-BRL). Equal amounts of cDNA were

25

subsequently amplified by PCR using specific primers for GAPDH

(Gen/EMBL accession no. AJ005371, sense:

ACCACAGTCCATGCCATCAC (SEQ ID NO: 7); antisense:

TCCACCACCCTGTTGCTGTA (SEQ ID NO: 8), Collagen I

5 (Gen/EMBL accession no. X55525, sense:

GGTCTTCCTGGCTTAAAGGG (SEQ ID NO: 9); antisense:

GCTGGTCAGCCCTGTAGAAG (SEQ ID NO: 10)), Collagen IV

(Gen/EMBL accession no. M11315, sense:

CCAGGAGTTCCAGGATTTCA (SEQ ID NO: 11); antisense:

10 TTTTGGTCCCAGAAGGACAC (SEQ ID NO: 12) and fibronectin

(Gen/EMBL accession no. X02761, sense:

CGAAATCACAGCCAGTAG (SEQ ID NO. 13), antisense:

ATCACATCCACACGGTAG (SEQ ID NO: 14)).

15 Fig. 3 depicts ethidium-stained panels of a 2% (w/v) agarose gel containing 10 µl of each PCR reaction after electrophoresis.

In Fig. 3 the lanes represent the following:

20 Lane 1: RT-PCR products from mesangial cells cultured in RPMI 1640 and 0.5% FBS;

Lane 2: RT-PCR products from mesangial cells exposed to rhCTGF (8 ng/ml) for 24 hr.

These results indicate that rhCTGF up-regulates mesangial cell collagens I and IV and fibronectin. These proteins typify matrix accumulation as seen in diabetic nephropathy.

5 CTGF is a member of a small family of highly homologous proteins termed the CCN family (for CTGF / fisp-12, cefl0/cyr61 and Nov) (Bork, P (1993). *FEBS Letts.* 327, 125-130.). These peptides are characterised by conservation of 38 cysteine residues that constitute more than 10 % of the amino acid content. All members have signal
10 peptides and appear to be secreted *via* orthodox secretory pathways (Bradham, D.M., (1991) *J. Cell. Biol.* 114, 1285-1294). In the context of diabetic nephropathy, it is intriguing that CTGF which is up-regulated in the presence of ambient glucose, in turn, up-regulates the production of extracellular matrix (ECM). These data demonstrate the potential of
15 CTGF as a stimulus for increased ECM synthesis and mesangial expansion in diabetic nephropathy.

Example 3

20 Enhanced CTGF expression in renal cortex and isolated glomeruli of rats with STZ-induced diabetic nephropathy.

To assess CTGF expression in diabetic nephropathy *in vivo*, CTGF mRNA levels were measured in RNA isolated from the cortex of
25 rats with STZ-induced diabetes mellitus. To this end, PCR primers for rat CTGF were designed from the sequence of the mouse CTGF homologue, fisp12 (Genbank/EMBL accession no. M70642, sense:

CTAAGACCTGTGGAATGGGC (SEQ ID NO: 15); antisense:
CTCAAAGATGTCATTGTCCCC (SEQ ID NO: 16)) (Ryseck, R.P.,
(1991) *Cell Growth Differ.* 2, 225-233).

5 RT-PCR was performed on total RNA extracted from renal
cortex of STZ-diabetic rats and age matched controls. The sequence of
the rat CTGF transcript was 94 % identical at the nucleotide level (Fig.
4) and 99 % identical at the amino acid level (Fig. 5) to the mouse
CTGF homologue fisp12 (bases 783-1123, accession no. M70642).

10 Nucleotides that differ between the two species are given in upper case
and the single different amino acid is in bold.

Induction of CTGF mRNA was observed in the renal cortex of
rats with STZ-induced diabetic nephropathy at four months after
15 administration of STZ, coincident with mesangial expansion and
proteinuria as shown in Fig. 6 and data not shown.

Fig. 6 depicts ethidium-stained panels of a 2 % (w/v) agarose gel
containing 10 µl of each PCR reaction after electrophoresis. CTGF and
20 GAPDH mRNA levels were analysed in total RNA purified from 2
diabetic animals with established nephropathy after four months of
diabetes (lanes 1 and 2) and two age matched control animals (lanes 3
and 4).

25 CTGF expression was further localized to glomeruli by RT-PCR
analysis of RNA extracted from glomeruli isolated by differential
sieving from the renal cortex of rats with STZ-induced diabetic

nephropathy. Glomerular levels of CTGF mRNA were increased by 2.5-fold and 1.6-fold after two months and four months of diabetes, respectively, by comparison with age and sex-matched controls. The significance of these observations is further supported by a recent report demonstrating CTGF expression in a screen of human renal diseases including diabetic nephropathy (Ito, Y., *et al.* (1998) *Kidney Int.* 53, 853-861).

Example 4

10 Induction of mesangial cell CTGF expression by high glucose involves TGF- β 1 dependent and independent pathways.

It has been shown that TGF- β 1 is a stimulus for mesangial matrix accumulation in diabetic nephropathy. In our experimental model as described in Example 1, high glucose concentrations provoked induction of TGF- β 1 mRNA expression in cultured human mesangial cells over the same temporal framework as CTGF expression (data not shown).

20 To assess the role of TGF- β 1 as a stimulus for CTGF expression in response to high glucose, cells were incubated in either 5 mM glucose or 30 mM glucose plus 1 μ l/ml anti-TGF- β 1 antibody for seven days with three changes of medium. Cells were serum starved for 24 hr in RPMI 1640 and 0.5% FBS. 10 ng/ml TGF- β 1 (Calbiochem) or 10
25 ng/ml TGF- β 1 preadsorbed with 1 μ g/ml neutralising anti-TGF- β 1 polyclonal antibody were subsequently added for 24 hr.

The role of PKC on CTGF expression in response to high glucose was investigated by culturing the mesangial cells in either 5 mM, 30 mM glucose or 30 mM glucose and the PKC inhibitor GF 102903X.

5

Fig. 7 is an autoradiograph of CTGF mRNA levels analysed by Northern Blot and depicts the results obtained when mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 hr in the presence (lane 3) and absence (lane 2) of anti-TGF- β 1 neutralising antibody (1 μ g/ml).
10 Cells cultured in RPMI 1640 and 0.5 % FBS for 24 hr served as control (lane 1). A 2.4 kb band was detected following hybridisation to the CTGF probe. The blot was stripped and reprobed with GAPDH. The relative amount of CTGF mRNA as estimated by Phosphor Imager quantification (Fig. 8). Values were normalised to GAPDH levels and
15 the results are representative of two independent experiments.

These results indicate that TGF- β 1 is a potent inducer of increased CTGF mRNA levels under these conditions. This effect was inhibited by the addition of a neutralising anti-TGF- β 1 antibody as
20 depicted in Fig. 7.

Fig. 9 is an autoradiograph of CTGF mRNA levels analysed by Northern Blot and depicts the results obtained when mesangial cells were exposed to 5 mM glucose (lane 1), 30 mM glucose (lane 2) and 30 mM glucose in the presence of anti-TGF- β 1 neutralising antibodies (1 μ g/ml) (lane 3) for seven days. A 2.4 kb band was detected following hybridisation to the CTGF probe. The blot was stripped and probed with
25

GAPDH. The relative amount of CTGF mRNA as estimated by Phosphor Imager quantification (Fig. 10). Values were normalised to GAPDH levels.

5 The neutralising anti-TGF- β 1 antibody partially attenuated the glucose-induced increase in CTGF transcript level in mesangial cells grown in 30 mM glucose for 7 days (Fig. 9), suggesting that high glucose triggers mesangial cell CTGF expression through TGF- β 1-dependent and independent pathways.

10

 Fig. 11 is an autoradiograph of CTGF mRNA levels analysed by Northern Blot and depicts the results obtained when mesangial cells were exposed to 5 mM glucose (lane 1), 30 mM glucose (lane 2) and 30 mM glucose in PKC inhibitor GF102903X (10 μ M) (lane 3) for four
15 days. A 2.4 kb band was detected following hybridisation to the CTGF probe. The blot was stripped and probed with GAPDH. The relative amount of CTGF mRNA as estimated by Phosphor Imager quantification (Fig. 12). Values were normalised to GAPDH levels.

20

 Whereas the PKC inhibitor GF102903X was without effect on TGF- β 1-induced CTGF expression in our system (data not shown), this compound afforded partial inhibition of high glucose-induced CTGF expression (Fig. 11).

25

 CTGF shares some of the biological actions of TGF- β 1 such as stimulation of cell proliferation and extracellular matrix protein synthesis in fibroblasts. When considered in this context, our results

suggest that TGF- β 1 may promote mesangial matrix production, in part, by inducing CTGF synthesis. TGF- β 1 has a complex profile of biological activities that includes pro-inflammatory, pro-fibrotic and anti-inflammatory effects. By targeting CTGF it may be possible to
5 attenuate the sclerosis-inducing effects of TGF- β 1 while preserving its more desirable anti-inflammatory activities.

Example 5

10 Further characterisation of IHG-2

IHG-2 is a mesangial cell gene which we have identified as being induced in human mesangial cells by high extracellular glucose as described in Example 1. To further characterise this gene, IHG-2 was
15 searched against the dbEST using the BLAST algorithm. This search identified a clone that was 94 % identical to ESTAA071138, clone no: 530117 3'. The sequence for the 5' end of this clone was also in the database, which again identified multiple ESTs. These ESTs showed homology with the 3' untranslated region (UTR) of a rat cDNA clone
20 known as drm/Gremlin. As indicated above, gremlin/drm, together with DAN and cerberus, are members of the cysteine knot super-family which includes TGF β and bone morphogenetic protein (BMP). A second EST W48852, clone no:324951 3', was identified from the IHG-2 BLAST. The 5' end of this clone, EST W48619, was also searched
25 against the database, from which EST AA373348 was obtained. This clone showed homology with the drm 3' UTR, approximately 500 bp from the open reading frame (ORF). Thus, it was possible to make a

direct link from IHG-2 to within 500 bp of the ORF of *drm/gremlin*. Therefore, by establishing a link between EST AA37348 and the ORF of *drm/gremlin*, it was confirmed that IHG-2 is part of the 3' UTR of this gene. Primers were designed to recognise the ORF, IHG-2, and the EST
5 clone AA373348. An initial PCR using primers corresponding to the start site of the *gremlin/drm* gene together with a primer within the IHG-2 clone would give a predicted product of approximately 2.5 kb. This product was nested with primers corresponding to the 3' end of the ORF of *gremlin* and the EST clone AA373348, generating a product of
10 approximately 500 bp, thus verifying that this EST is in the UTR of the human *drm/gremlin* gene. Therefore, IHG-2 was found to be part of the *drm/gremlin* gene, which was not previously known (Fig. 13).

Example 6

15

Use of cloning *in-silico* coupled with PCR to demonstrate that IHG-2 is
part of the 3' untranslated region of *gremlin*

In Example 5 we describe the identification of a transcript, IHG-2, the
20 sequence of which did not show homology against the cumulative database of characterised sequences using the BLAST algorithm.

Bioinformatic analysis was carried out as follows:

25

Database searching and alignments were performed at the National Center for Biotechnology Information (NCBI) Bethesda, Maryland, U.S.A. using the Basic Local Alignment Search Tool

Algorithm (BLAST) (Altschul, S.F., *et al.* (1997) *Nucleic Acids Res.* 25, 3389-3402). The Non Redundant (nr) and the Expressed Sequence Tag (EST) databases were sourced. Contiguous sequences were generated using Fragment Assembly, a program within the Genetics Computer
5 Group Inc. package. UniBlast (Guffanti, A., and Simon, G., *Trends in Genetics*, 14, 293) was used to identify homologous clusters within the UniGene database and to verify the consensus sequence derived from ESTs. Chromosomal localization data were obtained from the UniGene and Online Mendelian Inheritance in Man (OMIM) databases.

10

To further characterise the sequence, the sequence of IHG was searched against the EST database where a number of matches were obtained. Each of these matches was, in turn, searched against the nr database at NCBI. Four ESTs, namely W52686, N28395, H80042, and
15 W47324, showed low homology to the 3' UT region of the rat gene *drm* referred to in Example 5. The ORF of the human homologue of this gene, *gremlin*, was also in the database.

To generate a link between the ORF of *gremlin* and IHG-2,
20 successive BLAST searches were used to identify overlapping sequences in the EST database.

However, it was not possible to directly link IHG-2 to the ORF of *gremlin* with sequences within the EST database. Therefore, RNA
25 isolated from human mesangial cells was reverse transcribed with a primer that recognises IHG-2. PCR analyses were performed spanning the regions shown in Fig. 13.

In this graphical representation of a BLAST output from the EST database, the thick bar of 4 kb represents the final composite sequence of the gremlin gene. Each of the other bars represents an individual sequence, in the EST database, that were assembled, where possible, into continuous sequences, and demonstrates how cloning *in-silico* was used to generate the contiguous sequence. The region of no EST overlap was generated by reverse transcription of human mesangial mRNA with a complementary primer to IHG-2. PCR was performed spanning the regions indicated (by arrows), and the resulting products were sequenced, allowing a contiguous cDNA of 4049 bp to be generated which included the open reading frame of gremlin and IHG-2.

Human gremlin and rat *drm* cDNAs were compared and Fig. 14 shows a graphical representation of an alignment between rat *drm* and human gremlin together with the region corresponding to IHG-2 using the BLAST algorithm. Sequence homology was found to be high in the coding region of the cDNA; however, there are only small regions of homology within the 3' UT region. This explains why IHG-2 did not identify *drm* in a BLAST search, but a match to *drm*, and thus gremlin, was obtained by examining EST sequences further. The lack of homology between rat *drm* and human gremlin probably results from decreased selective pressure on the 3' UT region of gene homologues to remain the same between species.

Fig. 15 shows the final sequence of human mesangial cell gremlin, indicating the ORF and the region corresponding to IHG-2

(GenBank accession no: AF110137). Shown are the 5' and 3' UT sequence, and the open reading frame (with translation). The boxed region corresponds to the location of IHG-2. At the time of submission, this sequence matched 136 separate EST entries in the EST database. Of
5 these entries, 23.5% were derived from fibroblast libraries; 30% were from bone tissue libraries; and 34% were derived from tumor related libraries. The sequence was also searched against the UniGene database using the UniBlast program. This identified 4 UniGene clusters, Hs.214148, Hs.40098, Hs.114330, and Hs.239507. Two of these
10 clusters, Hs.40098, and Hs.239507, have been mapped to intervals D15S118-144 and D15S144-165 on chromosome 15, respectively. Secretory granule neuroendocrine protein 1 and the alpha polypeptide of the nicotinic cholinergic receptor have been mapped to either side of these clusters and have also been mapped more specifically to the
15 15q11-15 interval. Analysis of the OMIM database reveals that the formin gene, which was recently shown to induce gremlin expression in the developing limb bud (Zuniga, A., *et al.* (1999) *supra*), is also localised to this interval. Diabetes mellitus with multiple epiphyseal dysplasia, or Wolcott-Rallison syndrome, is localised to the 15q11-12
20 interval (Stewart, F.J., *et al.*, (1996) *Clin. Genet.* 49, 152-5). In the epiphyseal growth plate, immunohistochemical studies have revealed that BMP-2 and 4 are expressed in proliferating and maturing chondrocytes, suggesting that BMP and its receptors play roles in the multi-step cascade of enchondral ossification (Yazaki, Y., *et al.*, (1998) *Anticancer Res.* 18, 2339-44). Regulation of gremlin expression may
25 have implications in both of the disease states associated with Wolcott-Rallison syndrome.

Example 7

Induction of mesangial cell gremlin expression *in vitro* by high glucose
and cyclic mechanical strain induce

A) Primary cultures of human mesangial cells were propagated as described in Example 1, except that the medium was supplemented with 5% FBS. Treatment of cultures with glucose was carried out as described in Example 1. Mesangial cells were exposed to either 5m M glucose or 30mM glucose for seven days.

Northern Blot analysis as described further below was performed on RNA extracted from mesangial cells grown in either 5 mM ('normal') or 30 mM ('high') glucose using the ORF of gremlin and IHG-2 probes. Both probes detected a 2-fold increase in gene expression under high glucose conditions as depicted in Fig. 16.

All subsequent northern analysis was performed using the ORF of gremlin as a probe.

Northern Blots were performed using formaldehyde denaturation according to standard protocols and quantitated using a phosphorimager (Biorad). PCR products used to generate the probes for northern analysis were amplified using primers for the open reading frame (ORF) of gremlin (sense: ATGAGCCGCACAGCCTACAC (SEQ ID NO: 17); antisense TTAATCCAAATCGATGGATATGC (SEQ ID NO: 18)), and

for IHG-2 (sense: CTCAGCCTCCTAGCCAAGTCC (SEQ ID NO 19); antisense: GTATTGTCCACATTCTCCAAC (SEQ ID NO: 20)).

Fibronectin and GAPDH probes were generated as described in Example 2

5 Specific primers were used to amplify gremlin/IHG-2 (external sense: ATGAGCCGCACAGCCTACAC (SEQ ID NO: 21); external antisense: GTATTGTCCACATTCTCCAAC (SEQ ID NO: 22); internal sense: GAGAGTCACACGTGTGAAGC (SEQ ID NO: 23); internal antisense: AGGAGGATGCAAGCACAGG (SEQ ID NO: 24), BMP-2 (external
10 sense: CGCGGATCCTGCTTCTTAGACGGACTGCG (SEQ ID NO: 25); external antisense: TTTGCTGTACTAGCGACACC (SEQ ID NO: 26); internal sense: CAAGATGAACACAGCTGG (SEQ ID NO 27)), and GCTCAGGATACTCAAGAC (SEQ ID NO: 28)). RT-PCR was carried out as reported as described in Example 3.

15

The results are shown in Figs. 16 and 17.

In Figs. 16 and 17, lane 1 corresponds to the mesangial cells exposed to 5 mM glucose and lane 2 corresponds to the mesangial cells
20 exposed to 30 mM glucose.

Fig. 16 is an autoradiograph of IHG-2 (1), gremlin (2), fibronectin (3) and GAPDH (4) mRNA levels analysed by Northern Blot. Two bands of approximately 4.4 kb and 4.6 kb were detected
25 following hybridisation to the gremlin and IHG-2 probes.

Fig. 17 depicts relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels. The results are representative of three independent experiments.

- 5 B) Glomerular hypertension is an independent risk factor for the development of glomerulosclerosis in diabetes mellitus (Brenner, B.M., *et al.* (1982) *N. Engl. J. Med.* 307, 652-9). To model the effects of glomerular hypertension on mesangial cell gremlin expression in the present study, mesangial cells were propagated under conditions of
10 cyclic mechanical strain for 24 and 48 h in the Flexercell™ System

For the application of mechanical cyclic stretch, primary human mesangial cells were seeded on either flexible or rigid based, elastin coated six-well plates (Flex I and Flex II plates, Flex Cell™ Int,
15 Hillsborough, NH, USA). Cells were grown to 90% confluency, then serum restricted in Clonetics™ Mesangial Basal Medium supplemented with 0.5% fetal calf serum. Cells cultured on flexible plates were subjected to repeated cycles of computer-controlled, vacuum-driven mechanical stretch and relaxation using the Flexercell Strain Unit FX-
20 2000 (Flexercell™). Cells were alternately stretched and relaxed at 0.5 sec intervals (60 cycles/min) for either 24 or 48 h. The applied vacuum achieved a 17% elongation of the outer annulus of the culture plates. All experiments were carried out at 37°C and 5% CO₂ in a humidified incubator.

The results were obtained from three diabetic rats, 14 weeks following onset of diabetes and from three age matched controls.

5 The model used perturbs mesangial cell matrix production and metabolism in a manner similar to that observed in diabetic glomerulosclerosis *in vivo*. Mesangial cell gremlin mRNA levels were significantly enhanced under conditions of mechanical strain, in parallel with increased fibronectin mRNA expression as shown in Figs. 18 and 19.

10

Referring to Figs. 18 and 19 mesangial cells in culture were grown under static conditions (lane 1) or during exposure to cyclic stretch for 24 h (lane 2) or 48 h (lane 3) using the Flexercell™ System.

15

Fig. 18 is an autoradiograph of gremlin(1), fibronectin(2) and GAPDH(3) mRNA analysed by Northern Blot.

In Fig. 18 the lanes represent the following:

Lane 1: Mesangial cells grown in culture under static conditions;

20

Lane 2: Mesangial cells grown in culture during exposure to cyclic stretch for 24 h; and

Lane 3: Mesangial cells grown in culture during exposure to cyclic stretch for 48 h.

25

Fig. 19 depicts relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

To assess gremlin expression in diabetic nephropathy *in vivo*, gremlin mRNA levels were measured by Northern Blot analysis with RNA isolated from the renal cortex of control rats and from diabetic rats 14 weeks after induction of diabetes mellitus by streptozotocin (STZ).

5 In keeping with the *in vitro* experiments reported above, gremlin mRNA levels were increased in kidneys from diabetic rats, coincident with proteinuria and histologic evidence of diabetic nephropathy (data not shown).

10 Nine Male Munich-Wistar uninephrectomized rats were rendered diabetic with streptozotocin, and the RNA extracted as described in Example 3.

The results are shown in Figs. 20 and 21, which show gremlin
15 mRNA levels in renal cortex of STZ-diabetic rats.

Fig. 20 is an autoradiograph of gremlin mRNA levels in the kidney cortex of a STZ-diabetic rat (lane 2) and an age matched control (lane 1) analysed by Northern Blot. A band of approximately 4.4kb was
20 detected following hybridisation to the gremlin probe.

Fig. 21 depicts relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 8Regulation of mesangial cell gremlin expression by high glucose:
evidence for involvement of TGF- β 1

5

As indicated above, both high ambient glucose concentrations and cyclic mechanical strain provoke TGF- β 1 production by mesangial cells *in vitro* and TGF- β 1 appears to be a major stimulus for mesangial matrix accumulation in diabetic glomeruli *in vivo*. To probe the mechanism by which high glucose triggers gremlin expression, primary human mesangial cells were propagated in 5 mM or 30 mM glucose in the presence and absence of anti-TGF- β 1 neutralising antibody (1 μ g/ml). Treatment of cultures with glucose and anti-TGF- β 1 were as described in Example 1 and Example 4, respectively. To assess the role of TGF- β 1 as a stimulus for gremlin expression, cells were serum restricted for 24 h in MCDB131 and 0.5% FBS and subsequently treated with 10ng/ml TGF- β 1. MCDB131 is a specialised medium for the growth of mesangial cells and is obtained from Clonetics.

10

15

20

Initial studies had indicated that TGF- β 1 neutralizing antibody (data not shown) blunted glucose-triggered gremlin expression and therefore the ability of TGF- β 1 to alter gremlin expression was investigated. The results are shown in Figs. 22 and 23.

25

The addition of exogenous human recombinant TGF- β 1 (10 ng/ml, 24 h) to serum restricted (24 h) mesangial cells also augmented

gremlin mRNA levels, suggesting that high glucose enhances gremlin mRNA expression, at least in part, through its ability to stimulate TGF- β 1 expression. In aggregate, these observations suggest the presence of a novel autocrine loop through which TGF- β 1 induces gremlin gene expression and may thereby regulate the activity of mesangial-derived BMPs as hereinafter described.

It was found that gremlin expression in response to high glucose (30 mM, 7 days) was reduced in the presence of anti-TGF- β 1 antibody (data not shown). To further probe the role of TGF- β 1 as a modulator of gremlin expression, mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 h (lane 2). Cells cultured in MCDB131 and 0.5% FBS for 24 h served as a control (lane 1).

Fig. 22 is an autoradiograph of gremlin (1), fibronectin (2) and GAPDH (3) mRNA levels analysed by Northern Blot.

Fig. 23 shows relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 9High glucose stress induces BMP-2, but not BMP-4 expression in
mesangial cells.

As indicated above gremlin is a putative antagonist of BMP-2 and BMP-4. Specifically, gremlin has been recently reported to form heterodimers with BMPs and thereby antagonise BMP signalling (Hsu, D.R., et al. (1998) *supra*). In the present study, RT-PCR was employed as an initial assessment of mesangial cell BMP expression.

As an initial assessment of the relationship between gremlin expression and BMP expression, RNA was isolated from mesangial cells grown for 7 days in either 5mM or 30mM glucose. Following reverse transcription with random primers, a primary PCR of the ORF of BMP-2 was performed. This product, which was undetectable on an ethidium stained agarose gel after 30 cycles, was nested to give a predicted product of 446 bp. PCR analysis with BMP-4 and GAPDH specific primers gave predicted products of 378 bp and 452 bp respectively.

Fig. 24 depicts representative reactions of 4 independent experiments. 10uL of each PCR reaction was run on 1 % ethidium bromide stained agarose gels.

Whereas little or no BMP-2 mRNA was detected in mesangial cells propagated in 5 mM glucose, a marked induction of BMP-2 expression was observed in cells cultured in 30 mM glucose as shown in Fig. 24.

5

In contrast, BMP-4 expression levels were relatively unchanged. Interestingly, whereas BMP-2 does not stimulate fibronectin expression in mesangial cells *in vitro*, BMP-2 has been recently shown to block mesangial cell proliferation triggered by epidermal growth factor and platelet-derived growth factor (Ghosh Choudhury, G., *et al.*, (1999) *J. Biol. Chem.* 274, 10897-902; Ghosh Choudhury, G., *et al.*, (1999) *Biochem. Biophys. Res. Commun.* 258, 490-6). Our results raise the possibility that TGF- β 1 stimulated expression of gremlin may contribute to mesangial cell proliferative responses in this setting. The influence of gremlin on cell proliferation appears complex, however, and may vary markedly depending on the cell-type and proliferative stimulus. In contrast to the aforementioned potentially pro-proliferative actions, over-expression of the gremlin homologue, *drm*, causes apoptosis in fibroblasts by an ERK mediated pathway, while cells transformed with oncogenes such as *v-mos* show suppressed *drm* expression (Topol, L.Z., *et al.*, (1997) *Mol. Cell. Biol.* 17, 4801-10). Similarly, over-expression of DAN, another cysteine knot super-family member with homology to *drm/gremlin*, retards fibroblast entry into S phase (Ozaki, T., *et al.*, (1995) *Cancer Res.* 55, 895-900).

10

15

20

25

In summary, our results demonstrate that the DAN family member gremlin is induced in diabetic nephropathy *in vivo* and implicate both metabolic and hemodynamic stress as stimuli for gremlin expression.

5 The findings that high glucose-triggered gremlin expression is mimicked by addition of exogenous TGF- β 1, blunted by anti-TGF- β 1 neutralising antibody, and occurs in association with induction of mesangial cell BMP-2 suggests the presence of a novel autocrine loop which may limit the bioactivity of TGF- β 1 superfamily members and
10 modulate mesangial cell proliferation within the diabetic mesangium. The further elucidation of the functional interactions of the DAN family of secreted proteins, such as gremlin, with TGF- β 1 superfamily members may shed light on the complex multi-pronged molecular events that perturb cell proliferation and matrix production in diabetic
15 glomerulosclerosis.

Claims: -

1. A method for identifying a gene having a role in the presentation
5 of diabetic nephropathy, which method comprises culturing mesangial
cells in a medium in the presence of a concentration of glucose
sufficient to induce differential expression of a gene susceptible to such
differential expression and identifying the gene so induced.
- 10 2. A method according to Claim 1, wherein the mesangial cells are
cultured in the presence of a concentration of glucose sufficient to
induce up-regulation of a gene susceptible to such up-regulation.
- 15 3. A method according to Claim 1 or 2, wherein the concentration
of glucose is greater than 5 mM.
4. A method according to any preceding claim, wherein the
mesangial cells are subjected to mechanical strain.
- 20 5. A method according to any preceding claim, wherein
transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture
medium.
- 25 6. A method according to any preceding claim, wherein the
differentially expressed gene is identified by suppression subtractive
hybridisation.

7. A method according to any one of Claims 1-6, wherein the possibility of differential expression due to hyperosmolarity is excluded.

8. A method according to any one of Claims 1-7, wherein the gene so differentially expressed is a gene which includes a sequence selected from:

1) SEQ ID NOS: 1-3;

10 2) SEQ ID NO: 4;

3) SEQ ID NO: 5; and

4) SEQ ID NO: 6.

15

9. Use of a gene identified by a method according to any one of Claims 1-8, as a diagnostic marker for the progression and presentation of diabetic nephropathy.

20 10. Use of a gene identified by a method according to any of Claims 1-8, as an index of disease activity and the rate of progression of diabetic nephropathy.

25 11. Use of a gene identified by a method according to any of Claims 1-8, as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

12. A gene containing a sequence selected from any one of sequences 1-3, 5 and 6 according to Claim 8.

1/24




Fig. 1

2/24




Fig. 2

3/24




Fig. 3

4/24

[illegible]

Fig. 4

5/24

rat: 1 ISTRVTNDNTFCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKIAKPVKFELSGCTSV 180
mouse: 216 ISTRVTNDNTFCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKIAKPVKFELSGCTSV 275

rat: 181 KTYRAKFCGVCTDGRCCCTPHRTTTLPVEFKCPHGEIMKKNNMMFIKTCACHYNC 339 (SEQ ID NO: 31)
mouse: 276 KTYRAKFCGVCTDGRCCCTPHRTTTLPVEFKCPDGEIMKKNNMMFIKTCACHYNC 328 (SEQ ID NO: 32)

Fig. 5

6/24




Fig. 6

7/24




Fig. 7

8/24




Fig. 8

9/24




Fig. 9

10/24




Fig. 10

11/24




Fig. 11

12/24




Fig. 12




Fig. 13




Fig. 14

15/24

1 GCGGCCGCACTCAGCGCCACGCGTCTGAAAGCGCAGGCCCGGAGGACCGCCGCACTGACAGTATGAGCCGACAG
M S R T A
76 CCTACACGGTGGGAGCCCTGCTTCTCTCTTGGGGACCCTGCTGCGGGCTGCTGAAGGGAAAAAGAGGGTCCC
Y T V G A L L L L L G T L L P A A E G K K K G S Q
151 AAGGTGCCATCCCCCGCCAGACAAGGCCAGCACAATGACTCAGAGCAGACTCAGTCGCCCCAGCAGCTGGCT
G A I P P P D K A Q H N D S E Q T Q S P Q Q P G S
226 CCAGAAACCGGGGGGGGGCCCAAGGGCGGGGCACTGCCATGCCGGGGAGGAGGTGCTGAGTCCAGCCAAGAGG
R N R G R G Q G R G T A M P G E E V L E S Q E A
301 CCCTGCTGTGACGGAGCGCAAACTACCTGAAGCGAGACTGGTGCAAAACCCAGCCGCTTAAGCAGACCATCCAGC
L H V T E R K Y L K R D W C K T Q P L K Q T I H E
376 AGGAAGGCTGCAACAGTGCACCATCATCAACCGCTTCTGTTACGGCCAGTGCAACTCTTTTACATCCCCAGG
E G C N S R T I I N R F C Y G Q C N S F Y I P R H
451 ACATCCGGAAGGAGGAAGTTCTTTTCAGTCTGCTCTTCTGCAAGGCCAAGAATCTACTACCATGATGTGCA
I R K E E G S F Q S C S F C K P K K F T T M M V T
526 CACTCAACTGCCCTGAACTACAGCCACTTCAAGAAAGAGAGTACACGCTGGAAGCAGTGTGCTTGCAATAT
L N C P E L Q P P T K K R V T R V K Q C R C I S
601 CCATCGATTGGATTAAAGCCAAATCCAGGTGCACCCAGCATGTCTAGGAATGCAGCCCAGGAAGTCCCAGACC
I D L D
676 TAAACCAACGAGATTCTTACTTGGCTTAAACCTAGAGGCCAGAAGAACCCCCAGCTGCCTCTTGGCAGGAGCCTG
751 CTGTGCGTAGTTCGTGTGCATGAGTGTGGATGGGTGCCTGTGGGTGTTTTTAGACACCAGAGAAAACACAGTCT
826 CTGTCTAGAGACGACTCCCTATTTGTAACATATCTGCTTTAATGGGATGTACCCAGAAACCCACCTACCCCGG
901 CTCACATCTAAAGGGCGGGGCGCTTGTCTGCTTGTACTTGTGTTTTGTGCTCTCGGACCAGAAATCTC
976 CTTTCGGAATGAATGTTTCATGGAAGAGGCTCCTCTGAGGGCAAGAGACCTGTGTTTAGTCTGCACTTCGACATGGA
1051 AAGATCCTTTTAACCTGTGCTTGCACTCCTCTTCTCTCTCTCTCTCACATCCATCTCTTCTTAAGTTGATAGT
1126 GACTAGTGCAGTCAATCTCTTGTGGCAAGTTCCTAACTTAATCTACTTAACCATGCAAAATGTTTTTCA
1201 TTTTGTGAAGACCTCCAGACTCTGGGAGAGGCTGGTGTGGGCAAGGACAAGCAGGATAGTGAGGTGAGAAAGG
1276 AGGGTGGAGGGTGAGGCCAAATCAGGTCAGCAAAAAGTCACTAGGGACATGTGCAAGCTTGAAGGCCAATACC
1351 AGAACACAGGCTGATGCTCTGAGAAGTCTTTTCTAGTATTTAACAGAACCCAGTGAACAGAGGAGAAATGA
1426 GATTGCCAGAAAGTGATTAACCTTTGGCCGTTGCAATCTGCTCAAACTACCCAACTGAAACAACTAAATACTG
1501 ACCACTCCTATGTTCCGAGCCAAAGCAAGTTAGCTAAACCAAAACCACTCTCTGCTTTGCTCCTCAGGTGGAAAA
1576 GAGAGTAGTGTAGAACTCTCTGACATGGGGTGGGAATTAATCAAAACCKCAGAGGCTGAAATCTCTAATACCT
1651 TTCTTTTATCGTGGTTATAGTCAGCTCATTTCCATTTCCACTATTTTCCCACTAGCTCTGAGAGCCACTAATCTG
1726 ATTGATAAAGATCTCGCTCTGCTGAGTGTACCTGACAGTAACTTAAAGATGARAGAGTTTAGGACTACTCTG
1801 TTTTAGCAARATATGTTGGGGCTCTTTTGGTTTAACTATGTCCAGGAGATTTGGGCTARAGAGGAAGACGACGA
1876 GAGTAAGGAATAAAGGKRTTGCTCTGGTATGAGTAAGTTAGGTGTAAATCCTGGTAGAAATGAAGGGA
1951 TATGACCTCCCTTTCTTTATGTGCTCACTGAGGATCTGAGGGGACCCTGTTAGGAGAGTATGACATCATGATGTA
2026 TAGCTCTTCATCTGCTACTGTTGGATGGACATAACTATTGTAACTATTTCAGTATTACTGGTAGGACCTGCTC
2101 TCTGATTAACCTTGGCCATCTGGCAATGGCTACTTAGGATGTATCTAAGGGCCAAAGTCAGGGTGGGTGAACCT
2176 TATTCTACTTTGGATTGGTTAACTGTTTCTTCAAGCCTGAGGTTTTATATACAACTCCCTGAATACTCTTT
2251 TTGCTTGTATCTTCTCAGCCTCCTGACCAAGCTTATGTAATATGGAACCAACACTCAGACATCTTGAGATCTCA
2326 GTTGGCATCAAGGCTCTGGCATCTCAGGAACCTTGCAACTCAGAAAGCTGTTTTTATCTGTTTTTGTGTTGA
2401 TCCAGTGCTCTCCCATCAACAAGTAAACAGGAGCCATTTCAAGCGGGAGATATTTTAAACACCCAAATGTTG
2476 GGTCTGATTTTCAAACTTTTAAACTCACTAGTATGTTCTCAGCTCAGCGAATTTGTCACCAACTAGTGTCTC
2551 TGTGTTTGTATCAACTGTATGACCCCAACCCCACTTTGTTATGTGTCACATCTTCCACAAATAAGCAGAG
2626 TGGATTTAATTAAGCACACAAATGCTAAGGCAGAATTTTGAGGGTGGGAGAGAAGAAAGGGAAGAAGCTGAAA
2701 ATGTAAACACACAGGAGGAAAAATGACATTCAGAAGCAGCAAACTGAATTTCTCTTTGTTTAACTCT
2776 TGCCACAAGAATGCAATTTCTGTAATGAGATGACTTAAGTTGGCAGAGTAATCTCTTTTAGAGCTGTGACC
2851 ACAGTCTTGACATTAAGTGCAGATTGGCTCAAGTAAAGAGAATTTCTCAACACTAACTTCACTGGGATAATCA
2926 CGAGCGTAACTACCTTAAAAGCATATCACTAGCAAGAGGGAATATCTGTTCTTCTACTGTGCTATATTTAA
3001 GACTAGTACAAATGTGGTGTGCTTCCAACTTTCATTTGAAATGCCATATCTATACCATATTTTTCAGTCA
3076 TGATGATGTAATGATATATTTTTTTCATTATTATAGTAGAATATTTTTATGGCAAGATATTGTGGTCTTGATCAT
3151 ACCTATTAATAATGATGCAAAACCAATATGAATTTTATGATGTACACTTTGGTCTTGGCATTAAGAGAAAAA
3226 ACACACATCTCGGAAGTCTGTAGTGTGTTTTTGTACTGTAGTCTTCAAAGTTAAGAGTGAAGTGAAAAATC
3301 TGGAGGAGAGGATAATTTCCACTGTGTGGAATGTGAATAGTTAAATGAAAAGTTAGTGTTATTAATGTAAATAT
3376 TACTTCAATACCTTTGGTCACTGTGTTTCAAGCATGTTTCTTTCTCCTTTATATGACTTCTCTGAGTTGG
3451 GCAAGAAGAGCTGACACACCGTATGTTTGTAGTCTTTTACTGCTGAGGGAAACAAATCTCTGACCCAGC
3526 TGAACATGTCTTCTGAGTCAGTGCCTGAATCTTTATTTTTAAATGAAAGTTCCTTAAGGTTAACTATTTCTA
3601 AAGCAATTAAGAAGACTTTAAATGTTATTTTGGGAAGTATACGATGTCATGATACAAACGAATAGCAGATAA
3676 TGATGACTAGTTCACACATAAAGTCCTTTAAAGGACAAATCTAAATGAAAAGTGGATAAGAAAGAACATTTATA
3751 AGTGATCAGTTAATGCCTAAGAGTGAAGTAGTCTTATGACATTCCTCAAGATATTAAATCAACTGCATTAT
3826 GTATTATGTGCTGCTTAAATCATTTTAAACACGGCAAAAGAAATATATAGACTATGAGGTACCTTGCTGTGAGGAG
3901 ATGAAAGGGAGTGTGATAGTCTCATAAAACTAATTTGGCTTCAAGTTTTCATGAATCTGTAACTAGAATTTAAT
3976 TCACCCCAATAATGTTCTATATAGCTTTGCTAAGAGCAACTAATAAATTAACCTTACTCTTCAAAAAA

(SEQ ID NO: 33)

Fig. 15

16/24




FIG. 16

17/24




FIG. 17

18/24




FIG. 18




FIG. 19

20/24




FIG. 20

21/24




FIG. 21

22/24




Fig. 22

23/24




Fig. 23

24/24




Fig. 24

SEQUENCE LISTING

<110> HiberGen Limited
 University College Dublin, Nat Uni of Ire, Dublin
 Brady, Hugh Redmond
 Godson, Catherine Mary
 Martin, Finian Martin

<120> Identification of genes having a role in the
 presentation of diabetic nephropathy

<130> P00-18-PCT

<140>

<141>

<150> 990157

<151> 1999-02-26

<160> 33

<170> PatentIn Ver. 2.1

<210> 1

<211> 598

<212> DNA

<213> Homo sapiens

<400> 1

```

ttggaatagt tcttgcttta taaaaatagt actgcgatta aaaaaaaagc acttctgcc 60
aaggaaccat gttccaacac cgcaaacaag gtgttctgct taaacagagt aagatacacc 120
acccccatcc atcccttcc tccctgttcc cctcccaact tgagttgtgt cattcgcacc 180
agtgtcctgg gtggtaggga tgctacagcc acctaaggca aggagccctg ggaggtggga 240
gggcttgcat ggttaagcac accagaactg aagcgcaaaa gggtcagctg tcttcactta 300
gaatctctgg atgttccttc cagaaagcat ccccgatgat atcgcagtgc aagggcactg 360
gctttgtcct ggtccggggtc actgccatct tttttccttc catttctgtt ggcagcttaa 420
tttcttttgt catcacttca tccaccttct gccatatcaa cacagtccct ttcctataca 480
tcggcagctc attattatag ttgatgttga attcagaaaa caaaatctca ttcttgctctg 540
ctgnaagagt tccctgtaat ctcccttggg cttgtactgg tgttagtcca gattgttg 598

```

<210> 2

<211> 761

<212> DNA

<213> Homo sapiens

<400> 2

```

ggtcctttaaa agtctggttg ctgggataca ccacgactct tccgggtcaaa gcctggggga 60

```



```

tacagaaggg gctrgtcctc aaagtaatcc cgccaataaa acayatagct ggaggcaaac 120
tgggaggyca cgtgagtcac gaactttact ggctcttctt ttaaaccaat tggttttccg 180
cttgwacaca aagctgtact catcactctg tccataacgc gatcacaata tcctctagtt 240
cttccatcac agtctgcgca catttggtca tcagctggag agcacggctg tcattgggtt 300
ttgcaaagtt gtgcttctca gcaaaccgat ggaaattccg gccgtccagc cgnactacca 360
cccagcagtg tgccaggcag gtgtcgtcag cctcgaagtc cctcacgtac tcgaacttgc 420
tttttgccat ggtcgcccc aatctcaggt accgtctcag agtgatggaa atggtggcca 480
aggaatcgtg aaccttaact ttacaggcgc cccacattct acacgcggaa aggaaagggc 540
cagatagccc cgccccgaa gtgttctctt cgtggctact ctagccgtag ggcggtcata 600
gtctctctcg sctctccctg kagttcttaa mcyyccaggg aaaraggatg gaggtttagg 660
ttcctccgtt agcaccttcc acgcttgctt cttcctcctc ccggtctgcg gcaaatacgt 720
ctcacgaggt ttttaaaaat tattttttat ctgctggcct t 761

```

<210> 3

<211> 393

<212> DNA

<213> Homo sapiens

<400> 3

```

atgacacaaa tattaggatt ttatTTTTac tattatccac cagcaacaag atatcaaaca 60
ctggttctgt gattatttaa tggtgaaaaa gttgaataaa tcaatttagt ataccatat 120
gttggaatat tgagtccatt tttcttttaa aaatcacact ttggaataat tgatgatact 180
ggcaaagtct caagctgagt ggaaaaatat ataaacattg tataggcgaa taattccaat 240
cttgtgcatt ccctgtgtaa acctacatac acaaaaagaa aaaagactga aaggaaccat 300
ccacaatgct ttgatcggga aagacggaga aacaaagtg taattttctt aactatagtt 360
ttnggtgtat tccagatttt ctacaagtta ata 393

```

<210> 4

<211> 435

<212> DNA

<213> Homo sapiens

<400> 4

```

gtactttgga tttggttaac ctgttttctt caagcctgag gttttatata caaactccct 60
gaatactctt tttgccttgt atcttctcag cctcctagcc aagtcctatg taatatggaa 120
aacaacact gcagacttga gattcagttg ccgatcaagg ctctggcatt cagagaaccc 180
ttgcaactcg agaagctgtt tttatttcgt ttttgttttg atccagtgt ctcccatcta 240
acaactaaac aggagccatt tcaaggcggg agatatttta aacacccaaa atggttgggt 300
ctgattttca aactttttaa attcactact gatgattctg cacgctaagg cgaatttggg 360
ccaaacacat aagtgtgtgt gttttgtata cactgtatga cccacccca aatctttgta 420
ttgtccacat tctcc 435

```

<210> 5

<211> 273

<212> DNA

<213> Homo sapiens

<400> 5

```
agaagcaatt taggaanccn acagnaaana aatgctgttt tataggagag aaaacacggc 60
acaccaaggt taagtagttt gtagacgatg ttgaataggt tcaggtagag gtcaatgcag 120
tgatgaggaa agcacctang tatacttgac agatagtccc ctttgcttaa cacccaactc 180
ctccaccctg tgcagtttnn cttgtgccag tgatcacagg attcgctgag tgaattacca 240
taattggatt taattcacga aggggatgtt ttc 273
```

<210> 6

<211> 309

<212> DNA

<213> Homo sapiens

<400> 6

```
attgatagag gccctgtttc atgacatttc atgagtttca atatgttggt cagcatgttg 60
tgagggtgact ctcagccctt ttcccactga gatggactgt ggtgatgctg tgaggggtgtg 120
actgacacac cttcatgtgc ccaagcatgg gtttgatcac aggtcacatg cagtttttgg 180
catagtaaag gtatcattgt tcttttcctc cctcctaaag gaaacagagg aatccacctg 240
tatgagagtg ccatgtaggg ataaacttaa aggacagatg acacattggt catgttcgtg 300
ataaggaaa 309
```

<210> 7

<211> 20

<212> DNA

<213> Homo sapiens

<400> 7

```
accacagtcc atgccatcac 20
```

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

<400> 8

```
tccaccaccc tggtgctgta 20
```

<210> 9

<211> 20

<212> DNA

<213> Homo sapiens

<400> 9

ggtcttcctg gcttaaaggg 20

<210> 10

<211> 20

<212> DNA

<213> Homo sapiens

<400> 10

gctggtcagc cctgtagaag 20

<210> 11

<211> 20

<212> DNA

<213> Homo sapiens

<400> 11

ccaggagttc caggatttca 20

<210> 12

<211> 20

<212> DNA

<213> Homo sapiens

<400> 12

ttttggtccc agaaggacac 20

<210> 13

<211> 18

<212> DNA

<213> Homo sapiens

<400> 13

cgaaatcaca gccagtag 18

<210> 14

<211> 18

<212> DNA

<213> Homo sapiens

<400> 14

atcacatcca cacggtag 18

<210> 15
<211> 20
<212> DNA
<213> Homo sapiens

<400> 15
ctaagacctg tggaatgggc 20

<210> 16
<211> 21
<212> DNA
<213> Homo sapiens

<400> 16
ctcaaagatg tcattgtccc c 21

<210> 17
<211> 20
<212> DNA
<213> Homo sapiens

<400> 17
atgagccgca cagcctacac 20

<210> 18
<211> 23
<212> DNA
<213> Homo sapiens

<400> 18
ttaatccaaa tcgatggata tgc 23

<210> 19
<211> 21
<212> DNA
<213> Homo sapiens

<400> 19
ctcagcctcc tagccaagtc c 21

<210> 20
<211> 21
<212> DNA

<213> Homo sapiens

<400> 20

gtattgtcca cattctccaa c

21

<210> 21

<211> 20

<212> DNA

<213> Homo sapiens

<400> 21

atgagccgca cagcctacac

20

<210> 22

<211> 21

<212> DNA

<213> Homo sapiens

<400> 22

gtattgtcca cattctccaa c

21

<210> 23

<211> 20

<212> DNA

<213> Homo sapiens

<400> 23

gagagtcaca cgtgtgaagc

20

<210> 24

<211> 19

<212> DNA

<213> Homo sapiens

<400> 24

aggaggatgc aagcacagg

19

<210> 25

<211> 29

<212> DNA

<213> Homo sapiens

<400> 25

cgcggatcct gcttcttaga cggactgcg

29

<210> 26

<211> 20

<212> DNA

<213> Homo sapiens

<400> 26

tttgctgtac tagcgacacc

20

<210> 27

<211> 18

<212> DNA

<213> Homo sapiens

<400> 27

caagatgaac acagctgg

18

<210> 28

<211> 18

<212> DNA

<213> Homo sapiens

<400> 28

gctcaggata ctcaagac

18

<210> 29

<211> 341

<212> DNA

<213> Rattus sp.

<400> 29

atctccaccc gggttaccaa tgacaatact ttctgcaggc tggagaagca gagtcgtctc 60
 tgcattgtca ggccctgtga agctgacctt gagggaaaaca ttaagaaggc caaaaagtgc 120
 atccggacgc ctaaaattgc caagcctgtc aagtttgagc tttctggctg caccagtgtg 180
 aagacctacc gggctaagtt ctgtgggggtg tgcacggacg gccgctgctg cacaccgcac 240
 agaaccacca cactgccggt ggagttcaag tgcccccatg gcgaaatcat gaaaaagaac 300
 atgatgttca tcaagacctg tgcctgccat tacaactgtc c 341

<210> 30

<211> 341

<212> DNA

<213> Mus sp.

<400> 30

```

atctccaccc gagttaccaa tgacaatacc ttctgcagac tggagaagca gagccgcctc 60
tgcatggtca ggccctgcga agctgacctg gaggaaaaca ttaagaaggc caaaaagtgc 120
atccggacac ctaaaatcgc caagcctgtc aagtttgagc tttctggctg caccagtgtg 180
aagacataca gggctaagtt ctgcgggggtg tgcacagacg gccgctgctg cacaccgcac 240
agaaccacca ctctgccagt ggagttcaaa tgccccgatg gcgagatcat gaaaaagaat 300
atgatgttca tcaagacctg tgccctgccat tacaactgtc c 341

```

<210> 31

<211> 113

<212> PRT

<213> Rattus sp.

<400> 31

```

Ile Ser Thr Arg Val Thr Asn Asp Asn Thr Phe Cys Arg Leu Glu Lys
  1              5              10              15

```

```

Gln Ser Arg Leu Cys Met Val Arg Pro Cys Glu Ala Asp Leu Glu Glu
              20              25              30

```

```

Asn Ile Lys Lys Gly Lys Lys Cys Ile Arg Thr Pro Lys Ile Ala Lys
      35              40              45

```

```

Pro Val Lys Phe Glu Leu Ser Gly Cys Thr Ser Val Lys Thr Tyr Arg
      50              55              60

```

```

Ala Lys Phe Cys Gly Val Cys Thr Asp Gly Arg Cys Cys Thr Pro His
      65              70              75              80

```

```

Arg Thr Thr Thr Leu Pro Val Glu Phe Lys Cys Pro His Gly Glu Ile
              85              90              95

```

```

Met Lys Lys Asn Met Met Phe Ile Lys Thr Cys Ala Cys His Tyr Asn
      100              105              110

```

Cys

<210> 32

<211> 113

<212> PRT

<213> Mus sp.

<400> 32

```

Ile Ser Thr Arg Val Thr Asn Asp Asn Thr Phe Cys Arg Leu Glu Lys

```

1	5	10	15
Gln Ser Arg Leu Cys Met Val Arg Pro Cys Glu Ala Asp Leu Glu Glu			
20	25	30	
Asn Ile Lys Lys Gly Lys Lys Cys Ile Arg Thr Pro Lys Ile Ala Lys			
35	40	45	
Pro Val Lys Phe Glu Leu Ser Gly Cys Thr Ser Val Lys Thr Tyr Arg			
50	55	60	
Ala Lys Phe Cys Gly Val Cys Thr Asp Gly Arg Cys Cys Thr Pro His			
65	70	75	80
Arg Thr Thr Thr Leu Pro Val Glu Phe Lys Cys Pro Asp Gly Glu Ile			
85	90	95	
Met Lys Lys Asn Met Met Phe Ile Lys Thr Cys Ala Cys His Tyr Asn			
100	105	110	

Cys

<210> 33

<211> 4049

<212> DNA

<213> Homo sapiens

<400> 33

```

gcggccgcac tcagcgccac gcgtcgaaag cgcaggcccc gaggaccgcg cgcaactgaca 60
gtatgagccg cacagcctac acggtgggag ccctgcttct cctcttgggg accctgctgc 120
cggtgctga agggaaaaag aaagggtccc aagggtgcat ccccccgcga gacaaggccc 180
agcacaatga cttagagcag actcagtcgc cccagcagcc tggctccagg aaccgggggc 240
ggggccaagg gcggggcact gccatgcccg gggaggaggt gctggagtcc agccaagagg 300
ccctgcatgt gacggagcgc aaatacctga agcgagactg gtgcaaaacc cagccgctta 360
agcagacat ccacgaggaa ggctgcaaca gtcgcacat catcaaccgc ttctgttacg 420
gccagtgcaa ctctttctac atccccaggc acatccggaa ggaggaaggt tcctttcagt 480
cctgctcctt ctgcaagccc aagaattca ctaccatgat ggtcacactc aactgccctg 540
aactacagcc acctaccaag aagaagagag tcacacgtgt gaagcagtgt cgttgcatat 600
ccatcgattt ggattaagcc aaatccaggt gcaccagca tgccttagga atgcagcccc 660
aggaagtccc agacctaaaa caaccagatt cttacttggc ttaaacctag aggccagaag 720
aacccccagc tgctcctgg caggagcctg cttgtgcgta gttcgtgtgc atgagtgtgg 780
atgggtgcct gtgggtgttt ttagacacca gagaaaacac agtctctgct agagagcact 840
ccctattttg taaacatatc tgctttaatg gggatgtacc agaaaccac ctcaccccg 900
ctcacatcta aaggggaggg gccgtggtct ggttctgact ttgtgttttt gtgccctcct 960
ggggaccaga atctcctttc ggaatgaatg ttcattggaag aggtcctctt gagggcaaga 1020
gacctgtttt agtgctgcat tcgacatgga aaagtccttt taacctgtgc ttgcatcctc 1080

```


ctttcctcct	cctcctcaca	atccatctct	tcttaagttg	atagtgaacta	tgtcagtcta	1140
atctcttggt	tgccaaggtt	cctaaattaa	ttcacttaac	catgatgcaa	atgtttttca	1200
ttttgtgaag	accctccaga	ctctgggaga	ggctgggtg	ggcaaggaca	agcaggatag	1260
tggagtgaga	aagggagggt	ggagggtgag	gccaaatcag	gtccagcaaa	agtcagtagg	1320
gacattgcag	aagcttgaaa	ggccaatacc	agaacacagg	ctgatgcttc	tgagaaagtc	1380
ttttcctagt	atttaacaga	acccaagtga	acagaggaga	aatgagattg	ccagaaagtg	1440
attaactttg	gccgttgcaa	tctgctcaaa	cctaacacca	aactgaaaac	ataaatactg	1500
accactccta	tggtcggacc	caagcaagtt	agctaaacca	aaccaactcc	tctgctttgt	1560
ccctcaggtg	gaaaagagag	gtagtttaga	actctctgca	taggggtggg	aattaatcaa	1620
aaacckcaga	ggctgaaatt	cctaatacct	ttcctttatc	gtggttatag	tcagctcatt	1680
tccattccac	tatttcccat	aatgcttctg	agagccacta	acttgattga	taaagatcct	1740
gcctctgctg	agtgtacctg	acagtaagtc	taaagatgar	agagtttagg	gactactctg	1800
tttttagcaag	aratattktg	ggggtctttt	tgttttaact	attgtcagga	gattgggcta	1860
ragagaagac	gacgagagta	aggaaataaa	gggrattgcc	tctggctaga	gagtaagtta	1920
ggtgttaata	cctggtagaa	atgtaaggga	tatgacctcc	ctttctttat	gtgctcactg	1980
aggatctgag	gggacctgt	taggagagca	tagcatcatg	atgtattagc	tgttcatctg	2040
ctactggttg	gatggacata	actattgtaa	ctattcagta	tttactggta	ggcactgtcc	2100
tctgattaaa	cttggcctac	tggcaatggc	tacttaggat	tgatctaagg	gccaaagtc	2160
agggtgggtg	aactttattg	tactttggat	ttgggttaacc	tgttttcttc	aagcctgagg	2220
ttttatatac	aaactccctg	aatactcttt	ttgccttgta	tcttctcagc	ctcctagcca	2280
agtcctatgt	aatatggaaa	acaaacactg	cagacttgag	attcagttgc	cgatcaaggc	2340
tctggcattc	agagaaccct	tgcaactcga	gaagctgttt	ttatttcgtt	tttgttttga	2400
tccagtgtc	tcccatctaa	caactaaaca	ggagccattt	caaggcgga	gatattttaa	2460
acacccaaaa	tggtgggtct	gattttcaaa	cttttaact	cactactgat	gattctcacg	2520
ctaggcgaat	ttgtccaaac	acatagtggt	tgtgttttgt	atacactgta	tgacccacc	2580
ccaaatcttt	gtattgtcca	cattctccaa	caataaagca	cagagtggat	ttaattaagc	2640
acacaaatgc	taaggcagaa	ttttgagggt	gggagagaag	aaaagggaaa	gaagctgaaa	2700
atgtaaaacc	acaccaggga	ggaaaaatga	cattcagaac	cagcaaacac	tgaatttctc	2760
ttgttggttt	aactctgcca	caagaatgca	atttcgttaa	tggagatgac	ttaagttggc	2820
agcagtaatc	ttcttttagg	agcttgtagc	acagtcttgc	acataagtgc	agattttggct	2880
caagtaaaga	gaatttcctc	aacactaact	tactgggat	aatcagcagc	gtaactaccc	2940
taaaagcata	tactagcca	aagaggga	tatctgttct	tcttactgtg	cctatattaa	3000
gactagtaca	aatgtggtgt	gtcttccaac	tttcattgaa	aatgccatat	ctataccata	3060
ttttattcga	gtcactgatg	atgtaatgat	atattttttc	attattatag	tagaatattt	3120
ttatggcaag	atatttggtg	tcttgatcat	acctattaaa	ataatgcaa	acaccaaata	3180
tgaattttat	gatgtacact	ttgtgcttgg	cattaaaaga	aaaaaacaca	catcctggaa	3240
gtctgtaagt	tgttttttgt	tactgtaggt	cttcaaagtt	aagagtgtaa	gtgaaaaatc	3300
tggaggagag	gataatttcc	actgtgtgga	atgtgaatag	ttaaataaaa	agttatgggt	3360
atttaaatga	attattactt	caaactcctt	ggctactgtg	atttcaagca	tgttttcttt	3420
ttctccttta	tatgactttc	tctgagttgg	gcaaagaaga	agctgacaca	ccgtatgttg	3480
ttagagtctt	ttatctggtc	aggggaaaca	aaatcttgac	ccagctgaac	atgtcttcct	3540
gagtcagtgc	ctgaatcttt	attttttaaa	ttgaatgttc	cttaaagggt	aacattttcta	3600
aagcaatatt	aagaaagact	ttaaagtgtta	ttttggaaga	cttacgatgc	atgtatacaa	3660
acgaatagca	gataatgatg	actagttcac	acataaagtc	cttttaagga	gaaaatctaa	3720
aatgaaaagt	ggataaacag	aacatttata	agtgatcagt	taatgcctaa	gagtgaaagt	3780
agttctattg	acattcctca	agatatttaa	tatcaactgc	attatgtatt	atgtctgctt	3840
aaatcattta	aaaacggcaa	agaattatat	agactatgag	gtaccttgct	gtgtaggagg	3900
atgaaagggg	agttgatagt	ctcataaaac	taatttggtc	tcaagtttca	tgaatctgta	3960

actagaattt aattttcacc ccaataatgt tctatatagc ctttgctaaa gagcaactaa 4020
taaattaaac ctattctttc aaaaaaaaaa 4049

INTERNATIONAL SEARCH REPORT

Inter ☐ National Application No

PCT/IE 00/00026

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOLMES D I ET AL: "Identification of glucose -regulated genes in human mesangial cells by mRNA differential display." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1997 SEP 8) 238 (1) 179-84. XP000919240 the whole document	1-7
A	DATABASE EMSTS 'Online! EMBL, Heidelberg; Accession Number G38490, 24 June 1998 (1998-06-24) MYERS R.M.: "Human STSs 1998" XP002143063 abstract	12

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 July 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luzzatto, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IE 00/00026

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE EMBEST 'Online! EMBL, Heidelberg; Accession Number AA071138, 4 October 1996 (1996-10-04) HILLIER L. ET AL.: "Generation and analysis of 280000 human expressed sequence tags" XP002143064 abstract</p>	12
P,X	<p>MURPHY M ET AL: "Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells." JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 FEB 26) 274 (9) 5830-4. , XP002142860 the whole document</p>	1-7
P,X	<p>DATABASE EMHUM 'Online! EMBL, Heidelberg; Accession Number AK000553, 22 February 2000 (2000-02-22) SUGANO S. ET AL.: "NEDO human cDNA sequencing project" XP002143065 abstract</p>	12
P,X	<p>DATABASE GENESEQ 'Online! Derwent; Accession Number Z52443 (W0-A-9957144), 24 February 2000 (2000-02-24) HILLMAN J.L. ET AL.: "New peptides useful for diagnosis, prevention and treatment of cancer and immune disorders" XP002143066 abstract</p>	12
X	<p>DATABASE EMBEST 'Online! EMBL, Heidelberg; Accession Number N52279, 18 February 1996 (1996-02-18) HILLIER L. ET AL.: "The WashU-Merck EST project" XP002143067 abstract</p>	12